Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
1
American Association for Cancer Research Annual Meeting
UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER
April 1 – 5, 2017Washington, DCUCSF Presentation Brochure
As president of the UCSF Helen Diller Family Comprehensive Cancer
Center, one of my key priorities is to initiate and advance programs
that are developing new anticancer drugs making significant impact
on helping cancer patients live longer and better lives. I recognize this
goal is best accomplished by working in partnership with the broader
life science industry. This searchable abstract book of UCSF research
presented at AACR is a resource for potential partners interested in
identifying world-class faculty engaged in basic science and clinical
oncology research.
As an NCI-designated comprehensive cancer center, UCSF is
recognized for our outstanding science, extensive resources, depth
and breadth of our research in basic, clinical, and population sciences,
as well as cutting edge research that bridges these scientific areas.
Practically, this means that our clinicians and basic scientists work
closely together to (1) identify, develop, and optimize novel therapeutics
for biological efficacy and clinical utility, (2) assess tumor status and
responsiveness to current therapies, (3) develop biomarkers for patient
stratification and therapeutic response, and (4) advance supportive
care options to mitigate the toxicities associated with chemotherapy.
UCSF is home to many of world’s finest oncology clinicians and
scientists. I invite you learn more about our work and expertise
by reaching out to our faculty during this meeting. If you have any
additional questions or need any assistance with your outreach,
please contact the Director of Strategic Alliances for the Cancer
Center: Cammie Edwards ([email protected]).
Wishing you a very productive meeting and we look forward to
future discussions and collaborations.
Alan Ashworth, PhD, FRS President, UCSF Helen Diller Family Comprehensive Cancer Center
Committed to Advancing Development of Improved Cancer Therapies, Imaging Modalities, and Biomarkers
Alan Ashworth, PhD, FRSPresident, UCSF Helen Diller Family Comprehensive Cancer Center
Senior Vice President for Cancer Services, UCSF Health
Professor of Medicine, Division of Hematology/Oncology, Department of Medicine
2
The “comprehensive” designation—NCI’s highest ranking, awarded only after a rigorous evaluation process—recognizes UCSF’s excellence in basic research, clinical research, population based research, outreach and education, and our ability to integrate these diverse research approaches to cancer and turn them into clinical practice.
A Designated NCI Comprehensive Cancer Center Since 1999
HDFCCC Overview
Our Success is Driven by Our FacultyHDFCCC Membership: 415 Members & Affiliate Members2 Nobel Laureates
3 Albert Lasker Award winners
8 Howard Hughes Medical Investigators
14 Members of the National Academy of Sciences
20 Members of the Institute of Medicine
22 Fellows of the American Academy of Arts and Sciences
6 Fellows of the Royal Society
3
Working Together Advancing the Understanding and Treatment of Cancer
Multi-Disciplinary Research Programs• Breast Oncology
• Cancer Control
• Cancer Genetics
• Cancer, Immunity, and Microenvironment
• Developmental Therapeutics
• Hematopoietic Malignancies
• Neurologic Oncology
• Pediatric Malignancies
• Prostate Cancer
• Tobacco Control
Key Initiatives• Precision Imaging of Cancer and Therapy
• Cancer Immunotherapeutics
• Global Oncology
• Center for BRCA Research
• UCSF 500
• Cell Engineering
• Target Validation Initiative
• The San Francisco Cancer Initiative (SF CAN)
Multi-Disciplinary Clinical Programs • GU Oncology (non Prostate)
• GI (includes Pancreas Cancer)
• Thoracic Oncology
• Cutaneous Oncology
• Head and Neck Cancer
• Sarcoma
• Endocrine
• Gynecologic Oncology
• Breast Oncology
• Prostate Cancer
Translating Laboratory Discoveries into Improved Patient CareWhether it is advancing a new vaccine based immunotherapy, developing a new diagnostictest to distinguish benign moles from malignant melanoma or pioneering new adaptive clinicaltrial designs, UCSF success in translating laboratory discoveries into improved patient carecomes from its faculty and culture of exploration and collaboration. With over 400 facultyrelentlessly pursuing oncology research and clinical practice, we continue to make significantstrides in understanding the biology of disease and improving patient outcomes withadvanced clinical care.
HDFCCC Overview
4
• Biostatistics
• Clinical Research Support
• Genome Analysis
• Laboratory for Cell Analysis
• Immunohistochemistry & Molecular Pathology
• Mouse Pathology
• Preclinical Therapeutic Testing
• Bio-specimen Banking
• Tobacco Biomarkers
• Bioinformatics
• Computational Biology
UCSF consistently ranks among
the top U.S. biomedical research
organizations in cancer-specific
federal funding. In 2016, UCSF
received more than $92M from the
National Cancer Institute.
HDFCCC Overview
Core Capabilities Supporting Our Programs
Approximately one-quarter of the
University’s ~2,200 full-time faculty
members work in cancer research or
cancer care.
5
UCSF faculty have a long history of working with industry partners translating discoveries into products that ultimately improve patient care. We are experienced in establishing and executing on a wide range of successful partnerships. If you are interested in learning more about working with the HDFCCC and its faculty, please contact:
Cammie Edwards, PhDDirector of Strategic Alliances, HDFCCC
• On average, UCSF has 200-300 new invention disclosures per year
• An estimated 90 life science start-up companies have been spawnedfrom the University’s labs, including Genentech, Chiron, and Intellikine
• Included among UCSF patents are top revenue producers, such as
UCSF IN THE NEWS (Click on link to read story)
UCSF, Pfizer Renew Research Collaboration, Citing Progress in Drug Discovery Researchhttp://cancer.ucsf.edu/news/2017/01/09/ucsf-pfizer-renew-research-collaboration-citing-progress-in-drug-discovery-research.8092
Search Engine: How Artificial Intelligence Techniques Are Aiding the Hunt for New Drugshttp://cancer.ucsf.edu/news/2017/01/04/search-engine-how-artificial-intelligence-techniques-are-aiding-the-hunt-for-new-drugs.8079
New Targeted Chemotherapy Technology Proves Effective in Micehttp://cancer.ucsf.edu/news/2016/12/12/new-targeted-chemotherapy-technology-proves-effective-in-mice.8063
Mutant Protein Linked to Spread of Lung Cancer within the Bodyhttp://cancer.ucsf.edu/news/2016/11/21/mutant-protein-linked-to-spread-of-lung-cancer-within-the-body.7986
‘Cellbots’ Chase Down Cancer, Deliver Drugs Directly to Tumorshttp://cancer.ucsf.edu/news/2016/09/29/cellbots-chase-down-cancer-deliver-drugs-directly-to-tumors.7921
Dr. Amit Sabnis Awarded the 2017 AACR-Aflac, Inc. Career Development Award for Pediatric Cancer Research. The award will be used to further his research in identifying the molecular mechanism behind an oncogene-directed therapy in rhabdomyosarcoma and defining the PAX3-FOXO1 translatome.
- Hepatitis B vaccine
- Bovine growth hormone
- Barrier repair lipids
- Yeast expression vector
- Magnetic resonance imaging
Partnering with UCSF HDFCCC
Presentations
6 *UCSF authors in bold
Retooling CRISPR to turn genes on and off
Authors*: Luke A. Gilbert
Presentation #: Presentation Date/Time: April 1, 2017, 8:30 - 8:55AM Location: Room 207, Level 2, Washington Convention Center Presentation: Educational Session
Weissman Research Interests: Our laboratory is looking at how cells ensure that proteins fold into their correct shape, as well as the role of protein misfolding in disease and normal physiology. We are developing experimental and analytical approaches for exploring the organizational principles of biological systems and globally monitoring protein translation through ribosome profiling. Additionally, our research focuses on identifying and understanding the machinery necessary for efficient folding, as well as studying the mechanism and consequences of protein misfolding. We are also developing experimental and analytical approaches for exploring the organizational principles of complex biological systems and for monitoring protein translation in vivo with unprecedented precision and depth.
http://weissmanlab.ucsf.edu/research/research.html
__________________________________________________________________________
Brain cancer immunotherapy
Authors*: Hideho Okada
Presentation #: Presentation Date/Time: April 1, 2017, 10:15 - 12:15 PM Location: Independence Ballroom E-H, Meeting Level 4, Marriott Marquis DC Presentation: Educational Session
Okada Research Interests: As a translational physician scientist, Dr. Okada and his lab are focused on development of novel immunotherapeutic strategies for brain tumor patients. For example, Dr. Okada conducted one of the first immune gene therapy trials in patients with malignant glioma. His lab was also the first to identify and fully characterized cytotoxic T-lymphocyte epitopes for gliomas. Dr. Okada has also delineated the role of an integrin receptor very late activation antigen-4 and chemokine CXCL10 in efficient trafficking of T-cells to brain tumor sites. Dr. Okada has integrated these findings to develop a number of vaccine trials in both adult and pediatric glioma patients. More recently, his group developed a novel chimeric antigen receptor targeting glioblastoma cells, and are currently conducting a pilot trial.
http://neurosurgery.ucsf.edu/index.php/about_us_faculty_okada.html
PresentationsView full abstracts on line at: http://www.abstractsonline.com/pp8/#!/4292*UCSF authors in bold
Saturday, April 1, 2017
Presentations
7 *UCSF authors in bold
Tissue Tension: The extracellular martrix and PDAC phenotype
Authors*: Valerie M. Weaver Presentation #:Presentation Date/Time: April 1, 2017, 11:15 - 11:40 AM Location: Room 151, Level 1, Washington Convention Center Presentation: Educational Session
Weaver Research Interests: The extracellular matrix (ECM), the noncellular component of the microenvironment, influences cell growth, survival, migration and tissue-specific differentiation through a repertoire of cellular receptors including integrins, syndecans and discoidin receptors. We are exploring the molecular mechanisms whereby these ECM receptors modulate cell fate: specifically, how mechanical and topological properties of the matrix, which are related to its composition and organization, regulate the function of matrix receptors to alter cell behavior. Our research program is broadly divided into two fields of inquiry: (1) how matrix composition and organization influences mammary tissue development and tumor progression and (2) to clarify the role of matrix force on embryonic and adult stem cell fate.
http://weaverlab.ucsf.edu
__________________________________________________________________________
Transforming breast cancer treatment with CDK4/6 inhibitors
Authors*: Hope S. Rugo
Presentation #: Presentation Date/Time: April 1, 2017, 1:30 - 1:55 AM Location: Room 145, level 1, Washinton Convention Center Presentation: Educational Session
Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early & late stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage BC patients, including with UCSF’s Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations with large academic medical centers & consortia in order to expand the novel therapies available to patients. She was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the Alliance & is a founding member of the translational Breast Cancer Research Consortium where she co-leads the triple negative working group. She is on the novel agents committee and leads the safety committee for the neoadjuvant multi-center I SPY2 trial. At UCSF, Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients, families & friends from throughout the bay area.
http://cancer.ucsf.edu/people/profiles/rugo_hope.3648
Presentations
8 *UCSF authors in bold
Translating the cancer genome one codon at a time and its therapeutic implications
Authors*: Davide Ruggero
Presentation #: Presentation Date/Time: April 1, 2017, 1:00 - 1:25 PM Location: Room 206, Level 2, Washington Convention Center Presentation: Educational Session
__________________________________________________________________________
Response to checkpoint therapy and exhausted CTL in the tumor microenvironment
Authors*: Adil I. Daud
Presentation #: Presentation Date/Time: April 1, 2017, 1:00 - 1:20 PM Location: Ballroom C, Level 3, Washington Convention Center Presentation: Methods Workshop
Daud Research Interests: Our group at UCSF is focused on developing new immunotherapy agents and specifically understanding the biology of the immune response to PD-1 in melanoma. We developed IL- 12 gene therapy in melanoma and carried out the first in human clinical trial in 2005-2007. Based on this work, IL-12 electroporation is being explored in many cancers as an immune agent and as a combination treatment with PD-1 and other checkpoint inhibitors in melanoma. I have been involved in the development of anti-PD-1 antibodies for melanoma. With my colleagues Michael Rosenblum and Max Krummel at UCSF, we have developed a novel assay that profiles the intra-tumoral microenvironment in depth and can predict non-response to PD-1. We are currently exploring novel strategies for PD-1 non-responsive subsets of melanoma (and potentially other cancers).
http://cancer.ucsf.edu/people/profiles/daud_adil.3622
Presentations
9 *UCSF authors in bold
A beginner’s guide to perplexing clinical issues in pancreatic adenocarcinoma
Authors*: Margaret A. Tempero
Presentation #: Presentation Date/Time: April 1, 2017, 5:30 - 5:55 PM Location: Room 202, Level 2, Washington Convention Center Presentation: Special Session
Tempero Research Interests: Director of the UCSF Pancreas Center and Leader of the UCSF Pancreas Cancer Program, Dr. Tempero oversees research projects from risk assessment to early detection, biology, and therapeutics in PNET and PDAC. Her personal research career has focused on the area of investigational therapeutics in PDAC. She was a pioneer in the use of antibody-based therapies and helped develop the fixed dose rate concept for gemcitabine. Dr. Tempero’s group developed effective gemcitabine combinations and provided a foundation for using CA19-9 as a surrogate for survival, and is currently assessing molecular subtypes and molecular enrichment for selecting new drugs for clinical evaluation. She is a DreamTeam P.I. on a SU2C grant evaluating innovative immunotherapy approaches, and is co-PI on a U01 award to establish high risk cohorts for testing early diagnosis biomarkers. She has served as the NCCN Guidelines Panel Chair on Pancreatic Cancer since 2000, and on several SABs including the Mayo Clinic Pancreas Cancer SPORE and MDACC’s Moon Shot Program.
http://cancer.ucsf.edu/people/profiles/tempero_margaret.3701
Presentations
10 *UCSF authors in bold
Targeting BRD4 overcomes cetuximab resistance in HNSCC
Authors*: Toni Brand, Yan Zeng, Brandon Leonard, Rachel O’ Keefe, Hua Li, Daniel Johnson, Jennifer Grandis, Neil E. Bhola
Presentation #: 95 Presentation Date/Time: April 2, 2017, 1:00 pm - 5:00 pm Location: Section 4 Presentation: Poster Session/ Board #16
Head and Neck Cancer Lab: is dedicated to increasing our understanding of head and neck squamous cell carcinoma (HNSCC) to develop new treatment and prevention approaches. One overarching theme is to identify predictive biomarkers that will identify which treatment(s) are most effective for individual patients, thus allowing for personalized medicine. Translational resources we have developed to support our projects include a large collection of patient-derived xenografts (PDXs) and tissue microarrays containing over 500 human HNSCC research samples linked to a professionally curated clinical and pathologic database that includes information on treatment and survival. In addition to basic and translational research, we also have experience conducting investigator-initiated clinical trials of novel therapeutics, including an antisense EGFR (epidermal growth factor receptor) gene therapy and a novel decoy oligonucleotide targeting STAT3 (signal transducer and activator of transcription).
https://ohns.ucsf.edu/signaling-lab
__________________________________________________________________________
Silibinin suppresses bladder cancer through down-regulation of actin cytoskeleton and PI3K/Akt signaling pathways
Authors*: Mitsuho Imai-Sumida, Takeshi Chiyomaru, Shahana Majid, Priyanka Kulkarni, Pritha Dasgupta, Sharanjot Saini, Taku Kato, Shigekatsu Maekawa, Yutaka Hashimoto, Marisa Shiina, Guoren Deng, Varahram Shahryari, Hannah Nip, Rajvir Dahiya, Yuichiro Tanaka, Soichiro Yamamura
Presentation #: 199 Presentation Date/Time: April 2, 2017, 1:00 pm - 5:00 pm Location: Section 8 Presentation: Poster Session/ Board #28
Sunday, April 2, 2017
Presentations
11 *UCSF authors in bold
Site specific risk factors for colorectal cancer
Authors*: Samir Gupta, Ranier Bustamante, Ashley Earles, Maria E. Martinez, Karen Messer, Christina D. Williams, Andrew J. Gawron, Tonya Kaltenbach, Lin Liu
Presentation #: 281 Presentation Date/Time: April 2, 2017, 1:00 pm - 5:00 pm Location: Section 12 Presentation: Poster Session/ Board #25
Kaltenbach Research Interests: Dr. Kaltenbach is an active researcher and educator in the field of advanced endoscopic imaging and therapy. She has numerous publications on non-polypoid neoplasia, image enhanced endoscopy and endoscopic mucosal resection. She is currently leading a national intiative to measure and report colonoscopy quality across the VAs, and moreover, aims to improve colonoscopy quality through provider feedback and teaching. She played a major role in the recent efforts to enhance the quality of colonoscopy for the surveillance and management of dysplasia in inflammatory bowel disease throughout the world. These efforts have brought forward a practice paradigm that is built on evidence based medicine, and have included a new consensus guideline, atlas, teaching video and practice and implementation algorithm.
http://profiles.ucsf.edu/tonya.kaltenbach
__________________________________________________________________________
Regulation of macropinocytosis-dependent cell survival in pancreatic cancer cells
Authors*: Sung Eun Kim, Man-Tzu Wang, Frank McCormick
Presentation #:435 Presentation Date/Time: April 2, 2017, 1:00 pm - 5:00 pm Location: Section 18 Presentation: Poster Session/ Board #16
Presentations
12 *UCSF authors in bold
The role of miR-24 as a race-related genetic factor in prostate cancer
Authors*: Yutaka Hashimoto, Marisa Shiina, Taku Kato, Soichiro Yamamura, Yuichiro Tanaka, Shahana Majid, Sharanjot Saini, Varahram Shahryari, Priyanka Kulkarni, Pritha Dasgupta, Yozo Mitsui, Mitsuho Sumida, Guoren Deng, Laura Tabatabai, Deepak Kumar, Rajvir Dahiya
Presentation #: 462 Presentation Date/Time: April 2, 2017, 1:00 pm - 5:00 pm Location: Section 19 Presentation: Poster Session/ Board #3
Dahiya Research Interests: My group, which is part of the Urology Research Center at the VAMC/UCSF under the leadership of Dr. Peter Caroll, focuses on mechanisms of growth control in GU disorders, especially prostate and renal cancer. We have developed various novel methods for evaluating epigenetic pathways, microRNAs, gene regulation, and function in these diseases both in in vitro and in vivo models. In particular we are studying the role of microRNAs in the progression and metastasis of prostate cancer, diet, miRNAs, epigenetic changes in prostate cancer and wnt antagonist genes in kidney tumor progression and metastasis.
https://urology.ucsf.edu/people/rajvir-dahiya
__________________________________________________________________________
Differential expression of miR-34b and androgen receptor pathway regulate prostate cancer aggressiveness between African Americans and Caucasians
Authors*: Marisa Shiina, Yutaka Hashimoto, Taku Kato, Soichiro Yamamura, Yuichiro Tanaka, Shahana Majid, Sharanjot Saini, Shahryari Varahram, Priyanka Kulkarni, Prita Dasgupta, Mitsuho Sumida, Guoren Deng, Rajvir Dahiya
Presentation #: 483 Presentation Date/Time: April 2, 2017, 1:00 pm - 5:00 pm Location: Section 19 Presentation: Poster Session/ Board #24
Dahiya Research Interests: My group, which is part of the Urology Research Center at the VAMC/UCSF under the leadership of Dr. Peter Caroll, focuses on mechanisms of growth control in GU disorders, especially prostate and renal cancer. We have developed various novel methods for evaluating epigenetic pathways, microRNAs, gene regulation, and function in these diseases both in in vitro and in vivo models. In particular we are studying the role of microRNAs in the progression and metastasis of prostate cancer, diet, miRNAs, epigenetic changes in prostate cancer and wnt antagonist genes in kidney tumor progression and metastasis.
https://urology.ucsf.edu/people/rajvir-dahiya
Presentations
13 *UCSF authors in bold
Clustering analysis of next-generation sequencing T cell repertoire data in sipuleucel-T treated prostate cancer patients
Authors*: Li Zhang, Sounak Chakraborty, Jason Cham, David Oh, Nadeem Sheikh, Lawrence Fong
Presentation #: 549 Presentation Date/Time: April 2, 2017, 1:00 pm - 5:00 pm Location: Section 23 Presentation: Poster Session/ Board #10
Fong Research Interests: My lab focuses on how the immune system interacts with cancer as well as exploring tumor immunotherapies in mouse models and in patients. Our primary focus is in immunotherapy of GI and GU malignancies. We investigate how immunotherapies such as immune checkpoint inhibitors and cancer vaccines can enhance anti-tumor immunity both systemically and in the tumor microenvironment. Performing neoadjuvant immunotherapy trials, we determine how specific therapies can recruit immune effectors in cancer patients. Moreover, we have studied how clinical responders may differ from clinical non-responders. We are applying unbiased approaches to studying antigen-specific responses that are modulated in these patients and are currently developing biomarkers that may be predictive of clinical efficacy.
http://hemonc.ucsf.edu/fonglab/
__________________________________________________________________________
Mechanism of liver metastasis induced systemic suppression of checkpoint inhibitor response
Authors*: James C. Lee, Adil Daud, Jeff Bluestone
Presentation #: 683A Presentation Date/Time: April 2, 2017, 1:00 pm - 5:00 pm Location: Section 28 Presentation: Poster Session/ Board #30
Bluestone Research Interests: Our lab is broadly focused on understanding mechanisms regulating T cell activation. We have developed soluble receptor antagonists; mAbs & animals deficient in individual members of TCR & co-stimulatory pathways to define their individual roles in transplant rejection & autoimmunity including a special emphasis on regulatory T cells (Treg). We have also adapted animal studies to use biologics & cell-based therapies to develop therapeutics that can be used in humans with autoimmunity & under conditions of allotransplant rejection. A strong role for antigen-specific Tregs has been found in these model systems. Thus, the major goal of our work is to identify the antigen-specificity of thymic- & peripherally-derived Tregs with the expectation that these TCRs can be adapted for immunotherapy. Finally, our lab is determining mechanisms that control Treg stability with the goal of developing approaches using pharmacogenomics to either stabilize or destabilize Tregs in autoimmunity & cancer.
http://bluestone.ucsf.edu
Presentations
14 *UCSF authors in bold
TGFβ controls the DNA damage response via miR-182 regulation of BRCA1 and ATM
Authors*: Qi Liu, Haydeliz Martinez-Ruiz, John Murnane, Simon N. Powell, Mary Helen Barcellos-Hoff
Presentation #: 831 Presentation Date/Time: April 2, 2017, 1:00 pm - 5:00 pm Location: Section 39Presentation: Poster Session/ Board #9
Barcellos-Hoff Research Interests: The Barcellos-Hoff lab has actively pursued the translational potential of TGFβ inhibition in the context of radiotherapy in human cancer based on preclinical studies in mouse brain, breast, and lung tumor models. TGFβ inhibitors increase radiation sensitivity (i.e., 10-70% less dose is needed to reduce survival by 90%), inhibit molecular recognition of DNA damage, compromise DNA repair, and increases tumor control by radiation. Although most cancers are resistant to TGFβ growth control, most cancer cells appear to require TGFβ to effectively execute the genotoxic stress program, which provides a novel avenue to improve therapeutic response.
http://cancer.ucsf.edu/people/profiles/barcellos-hoff_mary.6915
__________________________________________________________________________
Asymmetric cell division regulator prevents hyperproliferation in glioma cell-of-origin
Authors*: Mathieu Daynac, Claudia K. Petritsch
Presentation #: 916 Presentation Date/Time: April 2, 2017, 1:00 pm - 5:00 pm Location: Section 43 Presentation: Poster Session/ Board #9
Petritsch Research Interests: The Petritsch Lab uses pharmacological, molecular, and in vivo and ex vivo techniques, to uncover the mechanism for cell fate decisions in oligodendrocyte precursor cells, in the healthy and diseased brain. Oligodendrocytes arise from oligodendrocyte precursor cells (OPCs) and accomplish myelination in the central nervous system to regulate axonal function. Although OPCs are the most abundant proliferative population in the adult and ageing brain, little is known about the underlying molecular regulation of OPC functions. In our lab, we are examining whether OPCs in the adult central nervous system decide about their fate by undergoing asymmetric divisions, whether the underlying mechanism of asymmetric cell divisions in mammalian cells diverge from the process found in Drosophila neuroblasts, whether this divergence involves epigenetic regulators and is there a cell intrinsic or extrinsic mechanism that determines whether OPC divisions are symmetrical or asymmetrical.
http://petritschlab.ucsf.edu
Presentations
15 *UCSF authors in bold
Oncology model fidelity scores
Authors*: Debajyoti Datta, Theodore Goldstein, Zhiping Gu, Atul Butte
Presentation #: LB-006 Presentation Date/Time: April 2, 2017, 1:00 pm - 5:00 pm Location: Section 34 Presentation: Poster Session/ Board #5
Butte Research Interests: Dr. Butte’s group builds and applies tools that convert more than 400 trillion points of molecular, clinical, and epidemiological data into diagnostics, therapeutics, and new insights into disease. This research has led to truly novel insights into ways to treat diseases and the founding of three investor-backed data-driven companies. His lab uses the bioinformatics methods that they have developed in-house to integrate, leverage, and reason over genomic, genetic, phenotypic, and other sources of molecular data to yield tools for physicians and patients. Additionally, his lab has developed tools for indexing public genomic data sets, re-mapping microarray data and in cloud-computing, as well as novel methods to explore human physiology using electronic health record data and in the medical risk estimation from whole genomes.
http://buttelab.ucsf.edu
__________________________________________________________________________
The Pediatric Brain Tumor Atlas: building an integrated, multi-platform data-rich ecosystem for collaborative discovery in the cloud
Authors*: Adam C. Resnick, Phillip B. Storm, Angela J. Waanders, Jena V. Lilly, Rishi R. Lulla, Sabine Mueller, Michael Prados, Leonard S. Sender, Allison Heath, Alex S. Felmeister, Anthony Cros, Yuankun Zhu, Pichai Raman
Presentation #: LB-008 Presentation Date/Time: April 2, 2017, 1:00 pm - 5:00 pm Location: Section 34 Presentation: Poster Session/ Board #7
Prados Research Interests: Dr. Prados is a world-recognized Neuro-oncology expert. He led the Adult Brain Tumor Consortium for over 15 years and founded the Pacific Pediatric Neuro-Oncology Consortium (PNOC), a multi-institutional consortium of now 15 major academic centers across the United States. Currently Dr. Prados is Professor Emeritus at UCSF devoting his efforts towards pediatric Neuro-Oncology clinical and translational research. He is the co-Project Leader of a pediatric brain tumor SPORE project at UCSF and is co-Project Leader of the PNOC. His major interests are early phase clinical trials research and the translational studies that precede and inform those trials in both adults and children. He is part of the Editorial board of Neuro-Oncology, Journal of Neuro-Oncology and Journal of Clinical Oncology, and a member of the NCI/CTEP Brain Malignancies Steering Committee. In 2014 he was awarded the Victor Levin Award for lifetime clinical research excellence from the Society of Neuro-Oncology.
http://cancer.ucsf.edu/people/profiles/prados_michael.3603
Presentations
16 *UCSF authors in bold
The NCI RAS Initiative at the Frederick National Laboratory for Cancer Research
Authors*: Frank McCormick, Frederick Streitz, Andrew Stephen, Frantz L. Jean-Francois, Thomas J. Turbyville -Invited Speakers Presentation #: Presentation Date/Time: April 2, 2017, 2:45 - 4:15 PM Location: Marquis Ballroom Salons 3-4, Meeting Level 2, Marriott Marquis DCPresentation: NIH Sponsored Section
__________________________________________________________________________
Meet the Research Icon: Bruce M. Alberts, PhD, Organized by the Associate Member Council (AMC)
Authors*: Bruce M. Alberts
Presentation #: Presentation Date/Time: April 2, 2017, 3:00 - 3:30 PM Location: AACR central Amphitheater (Booth 1125), Lower Level, Washington Convention Center Presentation: Meet the Research Icon
Presentations
17 *UCSF authors in bold
Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition
Authors*: Matthew J. Hangauer, Vasanthi S. Viswanathan, Matthew J. Ryan, Dhruv Bole, Jake Eaton, Stuart L. Schreiber, Frank McCormick, Michael T. McManus
Presentation #: 1006 Presentation Date/Time: April 2, 2017, 3:00 pm - 5:00 pm Location: Room 152, Level 1, Washington Convention CenterPresentation: Minisymposium
McManus Research Interests: The McManus lab studies fundamental processes relating to the regulation of gene expression. We take high-throughput approaches, analyzing hundreds of thousands to millions of experiments at once, using unique and complex libraries coupled to deep sequencing. Our systems span from cell culture to in vivo models, focusing on a broad array of disease relevant tissues. From cancer to diabetes, we develop novel technologies to help us better understand how genes are regulated and how they function in cells. We aim to uncover the dark matter of the genome, to help unravel the beautiful genomic complexity of pathways and how genes interact in development and disease.
http://mcmanuslab.ucsf.edu
__________________________________________________________________________
Selective impairment of intratumoral regulatory T cells by targeting Ezh2 enhances cancer immunity
Authors*: David Q. Wang, Jason R. Quiros, Chien-Chun S. Pai, Lawrence H. Fong, Jeffrey A. Bluestone, Michel J. DuPage
Presentation #: 1014 Presentation Date/Time: April 2, 2017, 3:00 pm - 5:00 pm Location: Room 146, Level 1, Washington Convention CenterPresentation: Minisymposium DuPage Research Interests: The DuPage lab is focused on examining the interface of the immune system and cancer. We aim to establish a new paradigm for augmenting immune responses against cancer by uncovering and subsequently targeting mechanisms that control T regulatory cell programming within the tumor microenvironment. We have identified key intracellular pathways, both signaling cascades and epigenetic enzymes, that when targeted, selectively reprogram intratumoral T regulatory cell function to enhance anti-cancer immunity. Our approach utilizes sophisticated genetic tools to modify T cells and tumor cells in a dynamic fashion during tumor progression and in the context of the most advanced pre-clinical cancer models of the human disease.
http://profiles.ucsf.edu/michel.dupage
Presentations
18 *UCSF authors in bold
Targeting the HSP40/HSP70 chaperone axis as a novel strategy to treat castration-resistant prostate cancer
Authors*: Michael A. Moses, Yeong Sang Kim, Genesis Rivera-Marquez, Matthew J. Watson, Sunmin Lee, Andrea Kravats, Sue Wickner, Jason Gestwicki, Jane Trepel, Len Neckers
Presentation #: 1180 Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon Location: Section 5 Presentation: Poster Session/ Board #25
Gestwicki Research Interests: We are interested in how molecular chaperones, such as Hsp70 and Hsp90, work together to maintain protein homostasis, which is the balance of protein folding, trafficking and turnover. Understanding this delicate balance is important because protein homeostasis is dramatically disrupted in many diseases, especially neurodegeneration and cancer. Our approach is to create small molecules that disrupt (or promote) interactions between chaperones. Using these chemical probes, we perturb protein-protein interactions and learn how this chaperone network is “wired”. These studies have taken us into many exciting areas of biotechnology and chemical biology.
http://gestwickilab.ucsf.edu
__________________________________________________________________________
FGFR inhibition re-sensitizes BRAF/MEK dual resistant cells to the BRAF/MEK inhibitor combination
Authors*: Victoria E. Wang, Jeffrey Settleman, Frank McCormick
Presentation #: 1209 Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon Location: Section 6 Presentation: Poster Session/ Board #24
Monday, April 3, 2017
Presentations
19 *UCSF authors in bold
Pathway analysis of insulin-like growth factor candidate genes and risk of pediatric rhabdomyosarcoma
Authors*: Libby Morimoto, XIaorong Shao, Anand Chokkalingam, Joseph Wiemels, Xiaomei Ma, Catherine Metayer
Presentation #: 1273 Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon Location: Section 11 Presentation: Poster Session/ Board #4
Wiemels Research Interests: The causes of most human cancers are unclear, but appear to be related to miscues in normal tissue developmental pathways, mutations (genetic and epigenetic) in critical genes caused by errors, infection, and chemicals, and a failure of recognition and removal of tumors by the immune system. Dr. Wiemels studies these factors as potential causes of hematopoietic and brain tumors. Large population-based studies of human cancer in the San Francisco Bay Area and State of California form a basis for examining the origin of these cancers, with a focus on future prevention. This type of research is highly collaborative, and Dr. Wiemels works with several epidemiologists, geneticists, clinicians, biologists, and statisticians.
http://profiles.ucsf.edu/joe.wiemels
__________________________________________________________________________
Genetic reclassification of prostate-specific antigen levels for personalized prostate cancer screening
Authors*: Rebecca E. Graff, Thomas J. Hoffmann, Michael N. Passarelli, Nima C. Emami, Lori C. Sakoda, Eric Jorgenson, Laurel A. Habel3, Jun Shan, Dilrini K. Ranatunga, Charles P. Quesenberry, Jr., Chun R. Chao4, Nirupa R. Ghai, David Aaronson, Joseph Presti, Tobias Nordström, Zhaoming Wang, Sonja I. Berndt, Stephen J. Chanock, Jonathan D. Mosley, Robert J. Klein, Mridu Middha, Hans Lilja, Olle Melander, Mark N. Kvale, Pui-Yan Kwok, Catherine Schaefer, Neil Risch, Stephen K. Van Den Eeden, John S. Witte
Presentation #: 1297 Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon Location: Section 11 Presentation: Poster Session/ Board #28
Witte Research Interests: Our research program encompasses a synthesis of methodological and applied genetic epidemiology, with the overall aim of deciphering the mechanisms underlying complex diseases and traits (Witte, Visscher & Wray, Nature Reviews Genetics 2014). Our methods work is focused on the design and statistical analysis of next-generation sequencing and genetic association studies. We are applying these methods to studies of cancer (e.g., of the prostate), birth defects, and pharmacogenomics.
http://wittelab.ucsf.edu/pages/research
Presentations
20 *UCSF authors in bold
Identification of pleiotropic cancer susceptibility variants from genome-wide association studies reveals functional characteristics
Authors*: Yi-Hsuan Wu, Rebecca E. Graff, Michael N. Passarelli, Thomas J. Hoffmann, Elad Ziv, John S. Witte
Presentation #:1310 Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon Location: Section 12 Presentation: Poster Session/ Board #11
Witte Research Interests: Our research program encompasses a synthesis of methodological and applied genetic epidemiology, with the overall aim of deciphering the mechanisms underlying complex diseases and traits (Witte, Visscher & Wray, Nature Reviews Genetics 2014). Our methods work is focused on the design and statistical analysis of next-generation sequencing and genetic association studies. We are applying these methods to studies of cancer (e.g., of the prostate), birth defects, and pharmacogenomics.
http://wittelab.ucsf.edu/pages/research
__________________________________________________________________________
Germline genetic signals across multiple aggressive prostate cancer phenotypes
Authors*: Caroline G. Tai, Nima C. Emami, Thomas J. Hoffmann, Lori C. Sakoda, Eric Jorgenson, Laurel A. Habel, Jun Shan, Dilrini K. Ranatunga, Chun R. Chao, Nirupa R. Ghai, David Aaronson, Joseph Presti, Catherine Schaefer, Neil Risch, Stephen K. Van Den Eeden, John S. Witte
Presentation #:1316 Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noonLocation: Section 12 Presentation: Poster Session/ Board #17
Witte Research Interests: Our research program encompasses a synthesis of methodological and applied genetic epidemiology, with the overall aim of deciphering the mechanisms underlying complex diseases and traits (Witte, Visscher & Wray, Nature Reviews Genetics 2014). Our methods work is focused on the design and statistical analysis of next-generation sequencing and genetic association studies. We are applying these methods to studies of cancer (e.g., of the prostate), birth defects, and pharmacogenomics.
http://wittelab.ucsf.edu/pages/research
Presentations
21 *UCSF authors in bold
Non-additive and interaction effects of HLA class 2 polymorphism contributing to risk of glioma
Authors*: Chenan Zhang, Kyle Walsh
Presentation #: 1320 Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon Location: Section 12 Presentation: Poster Session/ Board #21
Walsh Research Interests: Dr. Walsh’s research program is divided into two components: genetic epidemiology and functional genomics. The epidemiology component focuses on the use of genomic data from large population-based cohorts to identify the causes of cancer. This computational work stresses statistical methodologies for “gene hunting”, including GWAS, fine-mapping, admixture mapping, and whole-genome sequencing. This ongoing work has identified novel risk factors for glioma and childhood leukemia. The functional genomics component investigates the biological impact of genetic variants linked to cancer risk. Dr. Walsh’s laboratory utilizes numerous techniques, including: digital droplet PCR, ChIP, FISH, and luciferase reporter assays. Special focus is given to the interface of the inherited genome and the tumor genome. Deregulation of tumor suppression mechanisms, such as telomere-induced cell senescence, is of particular interest. http://neurosurgery.ucsf.edu/index.php/about_us_faculty_walsh
__________________________________________________________________________
Variable drug responses characterize the functional heterogeneity of Nf1 null tumors
Authors*: Daniela Pucciarelli, Ganesh Krishnamurthi, Steve Braunstein, Jean L. Nakamura
Presentation #: 1356 Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon Location: Section 14 Presentation: Poster Session/ Board #7
Nakamura Research Interests: The first area we study is Neurofibromatosis I (NF1), which is a genetic syndrome that can lead to tumors in children. Individuals with NF1 can develop brain tumors and tumors along their spines (as well as cancers in other organs). This is an incurable disease that can lead to many complications and even death. We have developed an experimental systems to study how mutations causing this disease actually lead to tumor formation, with the goal of using this information to develop better therapies. A second area of research is trying to understand why second cancers develop in some childhood cancer survivors. We analyze these second cancers from childhood cancer survivors (some of whom are now adults) for problems in the genetic code. By studying the abnormalities in the genetic code of second cancers, we expect to understand the biological processes leading to second cancers, and one day prevent these complications.
https://radonc.ucsf.edu/jean-nakamura
Presentations
22 *UCSF authors in bold
Structural basis of impaired GTP hydrolysis in oncogenic mutants of KRAS
Authors*: Timothy Tran, Sathiya Dharmaiah, Oleg Chertov, Timothy Waybright, William Gillette, Dominic Esposito, Dwight Nissley, Frank McCormick, Andrew Stephen, Dhirendra Simanshu
Presentation #: 1366 Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noonLocation: Section 14 Presentation: Poster Session/ Board #17
__________________________________________________________________________
EGFR-mediated Spred1 phosphorylation inhibits NF1 to sustain constitutive Ras/MAPK signaling
Authors*: Evan Markegard, Ellen L. Mercado, Jillian M. Silva, Jacqueline Galeas, Marena I. Trinidad, Anatoly Urisman, Frank McCormick
Presentation #: 1370 Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noonLocation: Section 14 Presentation: Poster Session/ Board #21
Presentations
23 *UCSF authors in bold
Systemic granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment increases T cell receptor diversity in localized and metastatic prostate cancer patients
Authors*: David Y. Oh, Li Zhang, Jason Cham, Alan Paciorek, Mark Klinger, Malek Faham, Susan F. Slovin, Lawrence Fong
Presentation #: 1694 Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon Location: Section 29 Presentation: Poster Session/ Board #13
Fong Research Interests: My lab focuses on how the immune system interacts with cancer as well as exploring tumor immunotherapies in mouse models and in patients. Our primary focus is in immunotherapy of GI and GU malignancies. We investigate how immunotherapies such as immune checkpoint inhibitors and cancer vaccines can enhance anti-tumor immunity both systemically and in the tumor microenvironment. Performing neoadjuvant immunotherapy trials, we determine how specific therapies can recruit immune effectors in cancer patients. Moreover, we have studied how clinical responders may differ from clinical non-responders. We are applying unbiased approaches to studying antigen-specific responses that are modulated in these patients and are currently developing biomarkers that may be predictive of clinical efficacy.
http://hemonc.ucsf.edu/fonglab/
__________________________________________________________________________
Chronic NSAID use increases survival in PIK3CA-altered head and neck squamous cell carcinoma
Authors*: Matthew Louis Hedberg, Noah Peyser, William Gooding, Hua Li, Toni Brand, Victor Olivas, Trever Bivona, Simion Choisea, Lin Wang, Jonas Johnson, Uma Duvvuri, Robert Ferris, Daniel Johnson, Patrick Ha, Julie Bauman, Jennifer Grandis
Presentation #: 1779 Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noonLocation: Section 32 Presentation: Poster Session/ Board #9
Grandis Research Interests: The Grandis lab has played a major role in determining the mutational landscape of head and neck squamous cell carcinoma (HNSCC) and is focused on determining the role of frequently mutated genes in this malignancy. PIK3CA is the most commonly altered is the most commonly altered oncogene in HNSCC. Prior work in colon cancer has suggested an association between regular aspirin use and extended survival in patients with PIK3CA mutations. Using a large cohort of patients with HNSCC, the Grandis lab has determined that chronic NSAID use is associated with dramatically improved survival in patients with altered PIK3CA. They have characterized the mechanism of action of PIK3CA mutations and the impact of NSAIDs on these mechanistic pathways. Further, they plan a large prospective clinical trial that will directly assess the therapeutic benefit of NSAIDs in HNSCC patients with specific mutational profiles.
http://cancer.ucsf.edu/people/profiles/grandis_jennifer.6048
Presentations
24 *UCSF authors in bold
Tumor-specific copy number alterations uncover therapeutic opportunities in osteosarcoma
Authors*: Leanne C. Sayles, Marcus Breese, Amanda L. Koehne, Stanley Leung, Aviv Spillinger, Alex Lee, Avanthi Shah, Krystal Straessler, Sheri Spunt, Neyssa Marina, Damon Jacobson, Raffi S. Avedian, David G. Mohler, Steven DuBois, Douglas S. Hawkins, E. Alejandro Sweet-Cordero
Presentation #: 1948 Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon Location: Section 42 Presentation: Poster Session/ Board #20
Sweet-Cordero Research Interests: My lab works to identify novel therapeutic approaches for cancer that target the genetic mutations and altered signaling networks specific to cancer cells. We use functional genomics applied to mouse and human systems (genetically engineered models, patient derived xenografts) to understand the transcriptional networks that regulate the outcome of specific oncogenic mutations and to understand how cancers become resistant to chemotherapy. We have two primary disease interests: lung cancer and pediatric sarcomas. Our lab has identified novel regulators of chemoresistance in lung cancer. We have used functional genomics in mouse and human models to identify a novel role for Wt1 in mediating KRAS-driven oncogenesis. We have identified and characterized the role of tumor-propagating cells in NSCLC and identified a key role for Notch3 as a self-renewal pathway in mouse and human NSCLC. In our sarcoma work, we are interested in mechanisms driving osteosarcoma and Ewing sarcoma progression.
https://cancer.ucsf.edu/people/profiles/sweetcordero_alejandro.8106
__________________________________________________________________________
STARTRK-NG: A phase 1/1b study of entrectinib in children and adolescents with advanced solid tumors and primary CNS tumors, with or without TRK, ROS1, or ALK fusions
Authors*: Ami V. Desai, Garrett M. Brodeur, Jennifer Foster, Suzanne Shusterman, Amit J. Sabnis, Magaret Macy, Cynthia Wetmore, Ellen Basu, Zachary Hornby, Vanessa Esquibel, Edna Chow Maneval, Pratik S. Multani, Elizabeth Fox
Presentation #: CT030 Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noonLocation: Section 33 Presentation: Poster Session/ Board #6
Sabnis Research Interests: Dr. Sabnis’s research uses patient-derived models to identify and pre-clinically validate new therapies for high-risk pediatric sarcomas. In work with his mentor, Dr. Trever Bivona, and other collaborators at UCSF, he has developed a nascent program focusing on targets within protein homeostasis networks. In addition, he sees patients within the Early Phase Clinical Trials group of the UCSF Benioff Children’s Hospital Division of Pediatric Hematology-Oncology.
http://cancer.ucsf.edu/people/profiles/sabnis_amit.7897
Presentations
25 *UCSF authors in bold
A phase Ib trial to study the safety and tolerability of atezolizumab with radium-223 dichloride in patients with metastatic castrate-resistant prostate cancer (mCRPC)
Authors*: Lawrence Fong, Michael Morris, Andrew Armstrong, Daniel Petrylak, Ulka Vaishampayan, Ajjai Alva, Jean Hoffman-Censits, Indrani Sarkar, Susheela Carroll, Christina Schiff, Oliver Sartor
Presentation #: CT031 Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon Location: Section 33 Presentation: Poster Session/ Board #7
Fong Research Interests: My lab focuses on how the immune system interacts with cancer as well as exploring tumor immunotherapies in mouse models and in patients. Our primary focus is in immunotherapy of GI and GU malignancies. We investigate how immunotherapies such as immune checkpoint inhibitors and cancer vaccines can enhance anti-tumor immunity both systemically and in the tumor microenvironment. Performing neoadjuvant immunotherapy trials, we determine how specific therapies can recruit immune effectors in cancer patients. Moreover, we have studied how clinical responders may differ from clinical non-responders. We are applying unbiased approaches to studying antigen-specific responses that are modulated in these patients and are currently developing biomarkers that may be predictive of clinical efficacy.
http://hemonc.ucsf.edu/fonglab/
__________________________________________________________________________
Copy number estimation from targeted amplicon-based next-generation sequencing of castration-resistant prostate cancer biopsies: analytic validation and clinical qualification for a iPARP clinical trial
Authors*: George Seed, Wei Yuan, Joaquin Mateo, Suzanne Carreira, Maryou Lambros, Gunther Boysen, Roberta Ferraldeschi, Susana Miranda, Ines Figueiredo, Ruth Riisnaes, Mateus Crespo, Daniel Nava Rodrigues, Eric Talevich, Dan Robinson, Priya Kunju, Yi-mi Wu, Robert Lonigro, Shahneen Sandhu, Arul Chinnayan, Johann De Bono
Presentation #: LB-044 Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon Location: Section 34 Presentation: Poster Session/ Board #6
Talevich Research Interests: Dr. Talevich is a bioinformatician in the Clinical Cancer Genomics Laboratory (CCGL) at the UCSF Medical center, supporting clinical care and translational research efforts in precision medicine, including the UCSF 500 cancer gene panel service. His area of focus is the design and construction of genomic analysis pipelines to support short-read (Illumina) DNA and RNA sequencing of cancer samples for patient care, and the development of software and databases for sample tracking, quality control, genome characterization and mutation calling, and functional annotation to facilitate clinical review.
http://profiles.ucsf.edu/eric.talevich
Presentations
26 *UCSF authors in bold
PARP-1 controls the DNA damage response by regulating E2F1 transcriptional activity
Authors*: Matthew J. Schiewer, Amy C. Mandigo, Nicolas Gordon, Fangjin Huang, Sanchaika Gaur, Shuang Zhao, Joseph Evans, Sumin Han, Theodore Parsons, Ruth Birbe, Peter McCue, Tapio Visakorpi, Ganesh Raj, Mark Rubin, Johann de Bono, Costas Lallas, Edouard Trabulsi, Leonard G. Gomella, Adam P. Dicker, Kevin Kelly, Beatrice Knudsen, Felix Feng, Karen E. Knudsen
Presentation #: LB-086 Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noonLocation: Section 36 Presentation: Poster Session/ Board #11
Feng Research Interests: Dr. Felix Feng is a leader in translational research in prostate cancer. The primary aim of Dr. Feng’s research program is to individualize therapy for patients with aggressive disease, by identifying determinants of treatment resistance and developing strategies to overcome this resistance. To enhance current clinical approaches from a biological perspective, his laboratory and dedicated research team are pursuing three major goals: 1) to identify novel molecular biomarkers of aggressive prostate cancer, 2) to understand the mechanisms by which several of these biomarkers drive disease progression, and 3) to develop therapeutic approaches to target these disease drivers. https://radonc.ucsf.edu/felix-feng
__________________________________________________________________________
Forcing tumor progression and aggression
Authors*: Valerie M Weaver
Presentation #: Presentation Date/Time: April 3, 2017, 11:20 - 11:40 AM Location: Room 202, Level 2, Washington Convention CenterPresentation: Major Symposium
Weaver Research Interests: The extracellular matrix (ECM), the noncellular component of the microenvironment, influences cell growth, survival, migration and tissue-specific differentiation through a repertoire of cellular receptors including integrins, syndecans and discoidin receptors. We are exploring the molecular mechanisms whereby these ECM receptors modulate cell fate: specifically, how mechanical and topological properties of the matrix, which are related to its composition and organization, regulate the function of matrix receptors to alter cell behavior. Our research program is broadly divided into two fields of inquiry: (1) how matrix composition and organization influences mammary tissue development and tumor progression and (2) to clarify the role of matrix force on embryonic and adult stem cell fate.
http://weaverlab.ucsf.edu
Presentations
27 *UCSF authors in bold
Landscape analysis of the initial data release from AACR Project GENIE
Authors*: Ethan Cerami, Alexander S. Baras, Justin Guinney, Eva Lepisto, Trevor J. Pugh, Nikolaus Schultz, Thomas Stricker, Shawn M. Sweeney, Laura J. van’t Veer, Gerrit A. Meijer, Fabrice Andre, Victor E. Velculescu, Kenna R. Shaw, Mia A. Levy, Philippe L. Bedard, Barrett J. Rollins, Charles L. Sawyers
Presentation #: LB-102 Presentation Date/Time: April 3, 2017, 11:55 - 12:05 PM Location: Ballroom A-B, Level 3, Washington Convention Center Presentation: Major Symposium
van’t Veer Research Interests: Dr. van ’t Veer’s research focuses on personalized medicine & advancing patient management based on knowledge of the genetic makeup of the tumor as well as the genetic makeup of the patient. Her laboratory investigates human kinases & how kinase inhibitors elicit response & resistance, which is also utilized to understand agent efficacy in the I-SPY 2 TRIAL. She is the PI of the Athena Breast Health Network, a 150,000 women cohort study evaluating new paradigms to enhance breast health. She leads the targeted genome testing of 100,000 women for 9 breast cancer susceptibility genes and a selection of ~100 known susceptibility SNPs. She is one of the PIs for the NIH Big Data to Knowledge Center Translational Genomics, facilitating worldwide standardization of sharing annotated genomics data.
http://cancer.ucsf.edu/people/profiles/vantveer_laura.3358
__________________________________________________________________________
MONARCH 1: Final overall survival analysis of a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease
Authors*: Hope S. Rugo, Sara M. Tolaney, Javier Cortés, Véronique Diéras, Debra A. Patt, Hans Wildiers, Shivani Nanda, Andrew G. Koustenis, Maura N. Dickler, José Baselga
Presentation #: CT044 Presentation Date/Time: April 3, 2017, 10:35 - 10:55 AM Location: Ballroom C, Level 3, Washington Convention Center Presentation: Clinical Trials Plenary Session
Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early & late stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage BC patients, including with UCSF’s Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations with large academic medical centers & consortia in order to expand the novel therapies available to patients. She was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the Alliance & is a founding member of the translational Breast Cancer Research Consortium where she co-leads the triple negative working group. She is on the novel agents committee and leads the safety committee for the neoadjuvant multi-center I SPY2 trial. At UCSF, Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients, families & friends from throughout the bay area.
http://cancer.ucsf.edu/people/profiles/rugo_hope.3648
Presentations
28 *UCSF authors in bold
Mechanisms of residual disease during targeted therapy
Authors*: Trever G. Bivona
Presentation #: Presentation Date/Time: April 3, 2017, 1:35 - 2:00 PM Location: Room 152, Level 1, Washington Convention Center Presentation: Major Symposium
Bivona Research Interests: Our team uses the tools of precision medicine to improve the molecular diagnosis and targeted therapy of patients with solid cancers, including lung cancer. Our program focuses on identifying and functionally characterizing the molecular drivers of tumor growth in individual patients. We study patient samples and clinical data to identify novel potential drivers of tumor initiation, progression, and therapy resistance. We functionally annotate the putative molecular drivers using an integrated approach of genetic and pharmacologic tools. This precision approach to understanding the molecular pathogenesis of lung cancer (and other cancers) has led to the discovery of new biomarkers and targets that provide rationale for novel clinical trials we are launching to improve patient survival.
http://www.bivonalab.net/
__________________________________________________________________________
Neonatal hormone levels and risk of testicular germ cell tumors (TGCT)
Authors*: Libby Morimoto, David Zava, Katherine McGlynn, Frank Stanczyk, Joseph Wiemels, Xiaomei Ma, Catherine Metayer
Presentation #: 2263 Presentation Date/Time: April 3, 2017, 1:00 pm - 5:00 pm Location: Section 11 Presentation: Poster Session/ Board #17
Wiemels Research Interests: The causes of most human cancers are unclear, but appear to be related to miscues in normal tissue developmental pathways, mutations (genetic and epigenetic) in critical genes caused by errors, infection, and chemicals, and a failure of recognition and removal of tumors by the immune system. Dr. Wiemels studies these factors as potential causes of hematopoietic and brain tumors. Large population-based studies of human cancer in the San Francisco Bay Area and State of California form a basis for examining the origin of these cancers, with a focus on future prevention. This type of research is highly collaborative, and Dr. Wiemels works with several epidemiologists, geneticists, clinicians, biologists, and statisticians.
http://profiles.ucsf.edu/joe.wiemels
Presentations
29 *UCSF authors in bold
Effects of tobacco smoking and alcohol consumption on risks of CYP1B1 polymorphisms for prostate cancer
Authors*: Taku Kato, Yutaka Hashimoto, Shigekatsu Maekawa, Marisa Shiina, Mitsuho Imai-Sumida, Pritha Dasgupta, Priyanka Kulkarni, Soichiro Yamamura, Shahana Majid, Sharanjot Saini, Varahram Sharryari, Guoren Deng, Rajvir Dahiya, Yuichiro Tanaka
Presentation #: 2288 Presentation Date/Time: April 3, 2017, 1:00 pm - 5:00 pm Location: Section 12 Presentation: Poster Session/ Board #12
Tanaka Research Interests: Dr. Tanaka’s research at the UC/VA Urology Research Center San Francisco over the years has involved a variety of areas that include methylation, polymorphism, non-coding RNA, aging, gene function and signaling pathways. Specifically, his research focuses on finding risk factors for urological cancers by utilizing human specimens, assessing the functional role of these biomarkers at the cellular and molecular levels and use of animal models, and determining its regulation in the cell; as he attempts to understand the mechanisms of the carcinogenesis process. The cancer types that he’s been studying involve prostate, kidney and bladder. By engaging in his research interest, results can lead to biomarkers as well as potential therapeutic implications for urological cancers.
https://www.ncire.org/research/researchers_by_name/Yuichiro-Tanaka-PhD/
__________________________________________________________________________
The long noncoding RNA SChLAP1 inhibits the SWI/SNF complex, revealing a therapeutic opportunity in prostate cancer
Authors*: Julia Dancourt, Anirban Sahu, John R. Prensner, Benjamin Chandler, Qi Cao, Nithin Edara, Udit Singhal, Matthew K. Lyer2, Rohit Malik, Xuhong Cao, Saravana M. Dhanasekaran, Yashar S. Niknafs, Shuang Zhao, Corey Speers, Arul M. Chinnaiyan, Felix Y. Feng
Presentation #: 2546 Presentation Date/Time: April 3, 2017, 1:00 pm - 5:00 pm Location: Section 21 Presentation: Poster Session/ Board #25
Feng Research Interests: Dr. Felix Feng is a leader in translational research in prostate cancer. The primary aim of Dr. Feng’s research program is to individualize therapy for patients with aggressive disease, by identifying determinants of treatment resistance and developing strategies to overcome this resistance. To enhance current clinical approaches from a biological perspective, his laboratory and dedicated research team are pursuing three major goals: 1) to identify novel molecular biomarkers of aggressive prostate cancer, 2) to understand the mechanisms by which several of these biomarkers drive disease progression, and 3) to develop therapeutic approaches to target these disease drivers.
https://radonc.ucsf.edu/felix-feng
Presentations
30 *UCSF authors in bold
Preclinical efficacy of daratumumab in acute lymphoblastic leukemia
Authors*: Karen Lee Bride, Tiffaney Vincent, Soo-Yeon L. Im, Tori Fuller, Theresa Ryan, David M. Barrett, Shannon L. Maude, Mignon L. Loh, Michelle L. Hermiston, Stephan A. Grupp, Brent L. Wood, David T. Teachey
Presentation #: 2642 Presentation Date/Time: April 3, 2017, 1:00 pm - 5:00 pm Location: Section 26 Presentation: Poster Session/ Board #1
Loh Research Interests: The Loh lab has focused on translating genomic and biochemical discoveries in juvenile myelomonocytic (JMML) and acute lymphoblastic leukemia (ALL) into assays and therapies that can be incorporated into clinical trials. Their work in JMML has largely focused on dissecting the genomic landscape of JMML, including descriptions of PTPN11 and CBL mutations and the discovery of CBL as a new familial tumor suppressor gene. From these discoveries, Dr. Loh established JMML CLIA molecular diagnostic testing, which is now utilized as standard testing for patients suspected of having JMML. Dr. Loh is currently Chair of the Children’s Oncology Group (COG) ALL committee starting in April 2015 and responsible for supervising and implementing the next generation of national ALL trials for children, adolescents, and young adults.
http://cancer.ucsf.edu/people/profiles/loh_mignon.3407
__________________________________________________________________________
STARTRK-2: A global phase 2, open-label, basket study of entrectinib in patients with locally advanced or metastatic solid tumors harboring TRK, ROS1, or ALK gene fusions
Authors*: Alexander Drilon, Kamalesh Kumar Sankhala, Stephen V. Liu, Byoung Chul Cho, Collin Blakely, Cheng E. Chee, Marwan Fakih, Jonathan Polikoff, Zachary Hornby, Lisa Schechet, David Luo, Edna Chow Maneval, Pratik S. Multani, Robert C. Doebele
Presentation #: CT060 Presentation Date/Time: April 3, 2017, 1:00 pm - 5:00 pmLocation: Section 33 Presentation: Poster Session/ Board #10
Blakely Research Interests: The primary focus of my research is to translate laboratory-based findings into novel investigator sponsored trials that aim to assess the safety and efficacy of rationally designed targeted therapies for lung cancer patients. My goals are to: 1) define how TKI resistance pathways evolve at the tumor genome, transcriptome and molecular signaling levels within lung cancers and to translate these findings into novel prognostic and predictive biomarkers that may predict TKI resistance before it occurs; 2) develop investigator sponsored clinical trials to test rational companion therapies that can prevent, delay, or overcome TKI resistance, 3) develop investigator sponsored clinical trials to target recently identified oncogenic pathways, outside of EGFR and ALK, that drive NSCLC; and 4) establish a cohort of patient-derived xenograft (PDX) mice to foster research that aims to further understand the molecular mechanisms of response and resistance to TKI therapies in lung cancer
http://top.ucsf.edu/meet-the-team/medical-oncologists/collin-blakely,-md,-phd.aspx
Presentations
31 *UCSF authors in bold
COP1 E3 ligase modulates response to oncogenic MAPK pathway
Authors*: Manasi K. Mayekar, Trever Bivona
Presentation #: LB-124 Presentation Date/Time: April 3, 2017, 1:00 pm - 5:00 pm Location: Section 35 Presentation: Poster Session/ Board #10
Bivona Research Interests: Our team uses the tools of precision medicine to improve the molecular diagnosis and targeted therapy of patients with solid cancers, including lung cancer. Our program focuses on identifying and functionally characterizing the molecular drivers of tumor growth in individual patients. We study patient samples and clinical data to identify novel potential drivers of tumor initiation, progression, and therapy resistance. We functionally annotate the putative molecular drivers using an integrated approach of genetic and pharmacologic tools. This precision approach to understanding the molecular pathogenesis of lung cancer (and other cancers) has led to the discovery of new biomarkers and targets that provide rationale for novel clinical trials we are launching to improve patient survival.
http://www.bivonalab.net/
Presentations
32 *UCSF authors in bold
Characterizing tumor-adjacent normal tissue: Is it really normal?
Authors*: Dvir Aran
Presentation #:Presentation Date/Time: April 4, 2017, 7:00 - 8:00 AMLocation: Marquis Ballroom Salons 3-4, Meeting Level 2, Marriott Marquis DCPresentation: NIH Sponsored Session
Butte Research Interests: Dr. Butte’s group builds and applies tools that convert more than 400 trillion points of molecular, clinical, and epidemiological data into diagnostics, therapeutics, and new insights into disease. This research has led to truly novel insights into ways to treat diseases and the founding of three investor-backed data-driven companies. His lab uses the bioinformatics methods that they have developed in-house to integrate, leverage, and reason over genomic, genetic, phenotypic, and other sources of molecular data to yield tools for physicians and patients. Additionally, his lab has developed tools for indexing public genomic data sets, re-mapping microarray data and in cloud-computing, as well as novel methods to explore human physiology using electronic health record data and in the medical risk estimation from whole genomes.
http://buttelab.ucsf.edu
__________________________________________________________________________
Cytoskeletal modulation results in increased tumor survival and drug resistance through attenuation of p53 dependent apoptosis
Authors*: Victoria E. Wang, John Doench, David Root, Rene Bernards, Jeffrey Settleman, Frank McCormick
Presentation #: 3182 Presentation Date/Time: April 4, 2017, 8:00 am - 12:00 noon Location: Section 7 Presentation: Poster Session/ Board #13
Tuesday, April 4, 2017
Presentations
33 *UCSF authors in bold
Genistein inhibits renal cancer progression through long non-coding RNA HOTAIR suppression
Authors*: Mitsuho Imai-Sumida, Shahana Majid, Pritha Dasgupta, Priyanka Kulkarni, Sharanjot Saini, Divya Bhagirath, Taku Kato, Shigekatsu Maekawa, Yutaka Hashimoto, Marisa Shiina, Guoren Deng, Varahram Shahryari, Yuichiro Tanaka, Rajvir Dahiya, Soichiro Yamamura
Presentation #: 3449 Presentation Date/Time: April 4, 2017, 8:00 am - 12:00 noonLocation: Section 18 Presentation: Poster Session/ Board #29
__________________________________________________________________________
LncRNA as potential target in drug-resistant melanomas
Authors*: Rosaura Esteve-Puig, Martina Sanlorenzo, Igor Vujic, Kevin Lai1,Marin Vujic, Dallas Mould, Kevin Lin, Juan Oses-Prieto, Shreya Chand, Christian Posch, Alma Burlingame, Susana Ortiz-Urda
Presentation #: 3493 Presentation Date/Time: April 4, 2017, 8:00 am - 12:00 noon Location: Section 20 Presentation: Poster Session/ Board #16
Ortiz-Urda Research Interests: The Ortiz lab is interested in the study of the functions of promoter and intronic sequences of melanoma related genes. Our lab studies the mechanisms of cancer progression and the resistance mechanisms to drugs. In addition, Ortiz’s lab uses novel nanotechnology approaches to detect mutations and to deliver specific drugs to the cells of interest. To study cancer progression, the Ortiz lab uses epithelial tissue and organotypic constructs as a model system. The latter encompass human skin regenerated on immune-deficient mice. Grafts can express different combination of genes allowing this the elucidation of factors that stimulate tumor progression. Furthermore, the Ortiz lab uses laser micro-dissection to study single cell genetics. In order to elucidate mechanisms of resistance to targeted therapeutics the Ortiz lab analyzes resistance melanoma cell lines at the level of genome and transcriptome.
http://cancer.ucsf.edu/research/ortiz-lab
Presentations
34 *UCSF authors in bold
Splice expression variation analysis (SEVA) for differential gene isoform usage in cancer
Authors*: Bahman Afsari, Theresa Guo, Michael Considine, Dylan Kelley, Emily Flam, Liliana Florea, Patrick Ha, Donald Geman, Michael F. Ochs, Joseph A. Califano, Daria A. Gaykalova, Alexander V. Favorov, Elana J. Fertig
Presentation #: 3577 Presentation Date/Time: April 4, 2017, 8:00 am - 12:00 noon Location: Section 23 Presentation: Poster Session/ Board #13
Ha Research Interests: Dr. Ha’s lab interests align with his clinical practice of managing patients with complex head and neck cancers. He has had multiple NIH grants examining the molecular underpinnings of salivary gland adenoid cystic carcinoma in order to learn more about this rare but deadly disease. He serves on the editorial board of several journals including Head and Neck and Oral Oncology, and is now serving as the Chief of Head and Neck Surgical Oncology at the University of California San Francisco.
http://ohns.ucsf.edu/patrick-ha
__________________________________________________________________________
Single cell RNA-Seq of primary lymphomas reveals the diverse transcriptional states of the cancer immunologic milieu
Authors*: Noemi Andor, Erin Simonds, Jiamin Chen, Christina Wood, Susan Grimes, Debra Czerwinski, Grace Zheng, Ronald Levy, Hanlee P. Ji
Presentation #: 3693 Presentation Date/Time: April 4, 2017, 8:00 am - 12:00 noon Location: Section 28 Presentation: Poster Session/ Board #6
Simonds Research Interests: I apply single-cell analysis techniques to understand how phenotypic heterogeneity contributes to cancer growth and resistance to therapy. I helped develop single-cell assays to study signaling in the healthy immune system, and in childhood leukemias and I am applying these same approaches to investigate phenotypic plasticity and immune infiltration in glioblastoma, the most common and lethal brain tumor. Many of my experiments are enabled by a next-generation flow cytometry platform (CyTOF mass cytometry), which can measure up to 42 protein expression and intracellular signaling markers at the single-cell level in millions of cancer cells. This platform provides detailed biochemical profiles of rare and complex samples, uncovering subpopulations that would have been overlooked by classical bulk protein and genetic assays.
http://profiles.ucsf.edu/erin.simonds#narrative
Presentations
35 *UCSF authors in bold
Identification of a novel and a shared H3.3K27M mutation derived neoantigen epitope and H3.3K27M specific TCR engineered T cell therapy for glioma
Authors*: Zinal Chheda, Gary Kohanbash, John Sidney, Kaori Okada, Naznin Jahan, Diego Carrera, Payal Watchmaker, Kira Downey, Shuming Liu, Shruti Shrivastav, Sabine Mueller, Ian F. Pollack, Angel M. Carcaboso, Alessandro Sette, Yafei Hou, Hideho Okada
Presentation #: 3767 Presentation Date/Time: April 4, 2017, 8:00 am - 12:00 noon Location: Section 30 Presentation: Poster Session/ Board #23
Okada Research Interests: As a translational physician scientist, Dr. Okada and his lab are focused on development of novel immunotherapeutic strategies for brain tumor patients. For example, Dr. Okada conducted one of the first immune gene therapy trials in patients with malignant glioma. His lab was also the first to identify and fully characterized cytotoxic T-lymphocyte epitopes for gliomas. Dr. Okada has also delineated the role of an integrin receptor very late activation antigen-4 and chemokine CXCL10 in efficient trafficking of T-cells to brain tumor sites. Dr. Okada has integrated these findings to develop a number of vaccine trials in both adult and pediatric glioma patients. More recently, his group developed a novel chimeric antigen receptor targeting glioblastoma cells, and are currently conducting a pilot trial.
http://neurosurgery.ucsf.edu/index.php/about_us_faculty_okada.html
__________________________________________________________________________
A subset of poorly prognostic pediatric posterior fossa ependymomas exhibit lowered H3K27me3 and DNA hypomethylation and show epigenetic similarities with H3K27M mutant diffuse intrinsic pontine gliomas
Authors*: Sriram Venneti, Jill Bayliss, Piali Mukherjee, Chao Lu, Siddhant Jain, Chan Chung, Daniel Martinez, Benjamin Sabari, Ashley Margol, Pooja Panwalkar, Abhijit Paroloia, Melike Pekmezci, Richard Mc Eachin, Marcin Cieslik, Benita Tamrazi, Benjamin Garcia, Gaspare La Rocca, Mariarita Santi, Peter Lewis, Cynthia Hawkins, Ari Melnick, C. David Allis, Craig B. Thompson, Arul Chinnaiyan, Alexander R. Judkins
Presentation #: 3863 Presentation Date/Time: April 4, 2017, 8:00 am - 12:00 noon Location: Section 38 Presentation: Poster Session/ Board #1
Pekmezci Research Interests: Dr. Pekmezci is a clinical Neuropathologist and Ophthalmic Pathologist, who is involved in translational research with specific focus on diagnostic and prognostic markers of CNS neoplasms. She has been particularly interested in molecular classification and grading schemes of diffuse gliomas. In addition, her ongoing research includes diagnostic and prognostic markers of ocular surface neoplasms and uveal melanomas.
https://www.pathology.ucsf.edu/about/faculty/pathology-mpekmezci.html
Presentations
36 *UCSF authors in bold
A novel combination therapy targeting BCL6 and phospho-STAT3 defeats intratumor heterogeneity in a subset of non-small cell lung cancers
Authors*: Dhruba Deb, Satwik Rajaram, Jill E. Larsen, Patrick P. Dospoy, Rossella Marullo, Longshan Li, Kimberley Avila, Leandro Cerchietti, John D. Minna1, Lani F. Wu, Steven J. Altschuler
Presentation #: 3950 Presentation Date/Time: April 4, 2017, 8:00 am - 12:00 noon Location: Section 41 Presentation: Poster Session/ Board #17
Altschuler and Wu Lab Research Interests: Over the past decade, our labs pioneered approaches for scalable, microscopy-based drug discovery. We also pioneered experimental, computational and theoretical approaches for identifying functional roles in patterns of cellular heterogeneity. We showed that patterns of cell-cell differences can reveal hidden biological information about how cells make decisions and serve as an informative readout of disease progression and drug response. Methodologies developed in our labs have been widely adapted in academics and industry.
http://cancer.ucsf.edu/people/profiles/altschuler_steven.5588
__________________________________________________________________________
NCoR2 regulates glioblastoma progression and treatment resistance
Authors*: Shelly Kaushik, Joanna J. Phillips, Valerie M. Weaver
Presentation #: 3985 Presentation Date/Time: April 4, 2017, 8:00 am - 12:00 noon Location: Section 42 Presentation: Poster Session/ Board #28
Weaver Research Interests: The extracellular matrix (ECM), the noncellular component of the microenvironment, influences cell growth, survival, migration and tissue-specific differentiation through a repertoire of cellular receptors including integrins, syndecans and discoidin receptors. We are exploring the molecular mechanisms whereby these ECM receptors modulate cell fate: specifically, how mechanical and topological properties of the matrix, which are related to its composition and organization, regulate the function of matrix receptors to alter cell behavior. Our research program is broadly divided into two fields of inquiry: (1) how matrix composition and organization influences mammary tissue development and tumor progression and (2) to clarify the role of matrix force on embryonic and adult stem cell fate.
http://weaverlab.ucsf.edu
Presentations
37 *UCSF authors in bold
Ribociclib + endocrine therapy (ET) doublet combinations in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Phase I clinical activity and impact of molecular alterations
Authors*: Dejan Juric, Mario Campone, Pamela Munster, Roohi Ismail-Khan, Laura Garcia Estévez, Mariana Chavez-MacGregor, Antonio Frassoldati, Rina Hui, Ingrid A. Mayer, Javier Cortés, Anthony Gonçalves, Richard H. De Boer, Luc Dirix, Sara M. Tolaney, Soo Chin Lee, Michela Maur, Yingbo Wang, Faye Su, Jason R. Dobson, Caroline Germa, Becker Hewes, Aditya Bardia
Presentation #: CT087 Presentation Date/Time: April 4, 2017, 8:00 am - 12:00 noon Location: Section 33 Presentation: Poster Session/ Board #5
Munster Research Interests: Our lab is interested in developing novel strategies to overcome hormone therapy resistance in breast cancer.
http://cancer.ucsf.edu/people/profiles/munster_pamela.3449
__________________________________________________________________________
Safety and pharmacodynamic activity of MEDI9197, a TLR 7/8 agonist, administered intratumorally in subjects with solid tumors
Authors*: Shilpa Gupta, Juneko Grilley-Olson, David Hong, Aurélien Marabelle, Pamela Munster, Rahul Aggarwal, Sandrine Aspeslagh, Robert G. Dixon, Manish Patel, Vivek Subbiah, Chris Morehouse, Yuling Wu, Jiping Zha, Leo Tseng, Zachary A. Cooper, Shannon Morris, Joshua Brody
Presentation #: CT091 Presentation Date/Time: April 4, 2017, 8:00 am - 12:00 noon Location: Section 33 Presentation: Poster Session/ Board #9
Presentations
38 *UCSF authors in bold
Precision medicine lessons from window-of-opportunity trials
Authors*: Jennifer Rubin Grandis
Presentation #:Presentation Date/Time: April 4, 2017, 9:15 - 9:45 AM Location: Hall D-E, Level 2, Washington Convention Center Presentation: Plenary Session
__________________________________________________________________________
Post-radiation mutational signatures
Authors*: Jean L. Nakamura
Presentation #:Presentation Date/Time: April 4, 2017, 12:04 - 12:30 PM Location: East Salon C, Level 1, Washington Convention Center Presentation: Special Session
Nakamura Research Interests: The first area we study is Neurofibromatosis I (NF1), which is a genetic syndrome that can lead to tumors in children. Individuals with NF1 can develop brain tumors and tumors along their spines (as well as cancers in other organs). This is an incurable disease that can lead to many complications and even death. We have developed an experimental systems to study how mutations causing this disease actually lead to tumor formation, with the goal of using this information to develop better therapies. A second area of research is trying to understand why second cancers develop in some childhood cancer survivors. We analyze these second cancers from childhood cancer survivors (some of whom are now adults) for problems in the genetic code. By studying the abnormalities in the genetic code of second cancers, we expect to understand the biological processes leading to second cancers, and one day prevent these complications.
https://radonc.ucsf.edu/jean-nakamura
Presentations
39 *UCSF authors in bold
Polygenic risk score for breast cancer risk prediction in Latinas: does one size fit all?
Authors*: Elad Ziv
Presentation #: Presentation Date/Time: April 4, 2017, 11:00 - 11:20 AM Location: Room 206, Level 2, Washington Convention Center Presentation: Major Symposium
Ziv Research Interests: Dr. Ziv joined the faculty at UCSF in 2001. His group focuses on identifying genetic variations that underlie risk for malignancies by using insights from epidemiology and population genetics. A major interest has been genetic susceptibility to breast cancer among Latinas. Using a combination of admixture mapping and genome wide association, they have identified genetic variants that are unique among Latinas and are associated with strong protection against breast cancer susceptibility. They are currently using a whole exome sequencing approach to identify breast cancer risk variants among Latinas. Dr. Ziv’s group has successfully mapped the genes for ethnic neutropenia in African Americans. They are also currently studying the genetic variation underlying multiple myeloma susceptibility and progression.
http://cancer.ucsf.edu/people/profiles/ziv_elad.3779
__________________________________________________________________________
“Weak links” in cancer proteostasis networks as new therapeutic targets
Authors*: Martin Kampmann
Presentation #: Presentation Date/Time: April 4, 2017, 10:30 - 12:30 PM Location: Marquis Ballroom Salons 1-2, Meeting Level 2, Marriott Marquis DC Presentation: Special Session
Kampmann Research Interests: In our research, we ask how cells maintain their proteins in a functional and balanced state. In human cells, this is accomplished by a network of over 1,000 different factors called the proteostasis network. Our goal is to understand how this network functions, and how it is challenged and rewired in disease states, in particular cancer and neurodegenerative diseases. Our functional genomics technology, which integrates CRISPR/Cas9-based control of gene function and large-scale genetic interaction maps, enables us to elucidate dynamic networks and to pinpoint nodes that are potential therapeutic targets. We use biochemistry, biophysics and cell biology to “zoom in” on individual nodes of the network and to reveal their mechanism of action.
http://kampmannlab.ucsf.edu
Presentations
40 *UCSF authors in bold
Minorities in Cancer Research Scientific Symposium: The Role of Diverse Populations in Precision Medicine
Authors*: Laura Fejerman
Presentation #:Presentation Date/Time: April 4, 2017, 10:30 - 12:30 PMLocation: Room 206, Level 2, Washington Convention CenterPresentation Type: Major Symposium
Fejerman Research Interests: Dr. Fejerman focuses on the discovery of genetic and non-genetic factors that contribute to breast cancer risk and prognosis in Latinas. Her past work established a relationship between genetic ancestry and breast cancer risk, where higher European ancestry in U.S. and Mexican Latinas was associated with an increased risk. Her subsequent research has built upon this observation, exploring genetic variants, through admixture mapping and genome-wide association approaches, as well as the possible environmental and lifestyle related factors, and ancestry-gene interactions. Recent work explores disparities in breast cancer prognosis by genetic ancestry in Latinas and its potential causes.
http://fejerman.ucsf.edu
__________________________________________________________________________
CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors
Authors*: Leisha Emens, John Powderly, I2, Lawrence Fong, Joshua Brody, Patrick Forde, Matthew Hellmann, Brett Hughes, Shivaani Kummar, Sherene Loi, Jason Luke, Daruka Mahadevan, Benjamin Markman, Ian McCaffery, Richard Miller, Ginna Laport
Presentation #: CT119 Presentation Date/Time: April 4, 2017, 12:18 - 12:33 PM Location: Ballroom C, Level 3, Washington Convention Center Presentation: Clinical Trials Plenary Session
Fong Research Interests: My lab focuses on how the immune system interacts with cancer as well as exploring tumor immunotherapies in mouse models and in patients. Our primary focus is in immunotherapy of GI and GU malignancies. We investigate how immunotherapies such as immune checkpoint inhibitors and cancer vaccines can enhance anti-tumor immunity both systemically and in the tumor microenvironment. Performing neoadjuvant immunotherapy trials, we determine how specific therapies can recruit immune effectors in cancer patients. Moreover, we have studied how clinical responders may differ from clinical non-responders. We are applying unbiased approaches to studying antigen-specific responses that are modulated in these patients and are currently developing biomarkers that may be predictive of clinical efficacy.
http://hemonc.ucsf.edu/fonglab/
Presentations
41 *UCSF authors in bold
Vaccination in patients with low-grade glioma aiming at prevention of high-grade transformation
Authors*: Hideho Okada
Presentation #:Presentation Date/Time: April 4, 2017, 1:25 - 1:45 PM Location: Ballroom C, Level 3, Washington Convention Center Presentation: Rapid Advances in Prevention Research
Okada Research Interests: As a translational physician scientist, Dr. Okada and his lab are focused on development of novel immunotherapeutic strategies for brain tumor patients. For example, Dr. Okada conducted one of the first immune gene therapy trials in patients with malignant glioma. His lab was also the first to identify and fully characterized cytotoxic T-lymphocyte epitopes for gliomas. Dr. Okada has also delineated the role of an integrin receptor very late activation antigen-4 and chemokine CXCL10 in efficient trafficking of T-cells to brain tumor sites. Dr. Okada has integrated these findings to develop a number of vaccine trials in both adult and pediatric glioma patients. More recently, his group developed a novel chimeric antigen receptor targeting glioblastoma cells, and are currently conducting a pilot trial.
http://neurosurgery.ucsf.edu/index.php/about_us_faculty_okada.html
__________________________________________________________________________
Overcoming kinase inhibitor resistance and dealing with biologic redundancy: mTOR and K-Ras
Authors*: Kevan Michael Shokat
Presentation #: Presentation Date/Time: April 4, 2017, 2:05 - 2:30 PM Location: Room 207, Level 2, Washington Convention Center Presentation: Major Symposium
Presentations
42 *UCSF authors in bold
Identifying allosteric modulators of KRas using second harmonic generation
Authors*: Elizabeth Donohue Vo, Gabriel Besserer Mercado, Patrick Alexander, Ben Moree, Que Van, Andrew G. Stephen, Joshua Salafsky, Frank McCormick
Presentation #: 4018 Presentation Date/Time: April 4, 2017, 1:00 pm - 5:00 pm Location: Section 1Presentation: Poster Session/ Board #8
__________________________________________________________________________
Targeting the EGFR/STAT3 axis in NSCLC with resistance to EGFR tyrosine kinase inhibitors using an oligonucleotide-based decoy
Authors*: Christian Njatcha, Mariya Farooqui, Jennifer R. Grandis, Jill M. Siegfried
Presentation #: 4101 Presentation Date/Time: April 4, 2017, 1:00 pm - 5:00 pm Location: Section 4 Presentation: Poster Session/ Board #11
Presentations
43 *UCSF authors in bold
Targeting IL-6 signaling overcomes cetuximab resistance in head and neck squamous cell carcinoma
Authors*: Rachel A. O’Keefe, Neil Bhola, Toni M. Brand, Yan Zeng, Daniel E. Johnson, Jennifer R. Grandis
Presentation #: 4108 Presentation Date/Time: April 4, 2017, 1:00 pm - 5:00 pm Location: Section 4 Presentation: Poster Session/ Board #18
Grandis Research Interests: Cetuximab is an EGFR monoclonal antibody that is FDA-approved for the treatment of head and neck cancer. Despite ubiquitous over expression of EGFR in head and neck cancers, only a subset of patients respond to this drug and resistance mechanisms are incompletely understood. The Grandis lab has accumulated evidence that secretion of interleukin 6 (IL6), with subsequent oncogenic signaling represents a potential pathway of cetuximab resistance where co-targeting IL6/ILR-receptor may represent a plausible therapeutic strategy.
http://cancer.ucsf.edu/people/profiles/grandis_jennifer.6048
__________________________________________________________________________
Application of convolutional neural networks to breast biopsies to uncover tissue correlates of mammographic breast density
Authors*: Maeve Mullooly, Babak Ehteshami Bejnordi, Maya Palakal, Pamela M. Vacek, Donald L. Weaver, John A. Shepherd, Bo Fan, Amir Pasha Mahmoudzadeh, Jeff Wang, Jason M. Johnson, Sally D. Herschorn, Brian L. Sprague, Ruth M. Pfeiffer, Louise A. Brinton, Mark E. Sherman, Andrew Beck, Gretchen L. Gierach
Presentation #: 4235 Presentation Date/Time: April 4, 2017, 1:00 pm - 5:00 pm Location: Section 11 Presentation: Poster Session/ Board #1
Shepherd Research Interests: Dr. Shepherd’s research interests involve quantitative imaging methods for tissue composition using x-rays. His mammographic methods are used extensively for research around the world and in the San Francisco Mammography Registry Program. Dr. Shepherd’s efforts are focused on the technical imaging aspects of the measurements of the body composition and the translation of these measurements into different fields of study. He has present and future research projects in the following areas: breast cancer risk and detection using breast density and tissue texture measures; dual-energy x-ray diagnostic mammography for characterizing compositional signatures of cancer lesions; total body protein measures, body shape analysis and metabolic diseases; statistics of quality assurance and quality control for quantitative measurements.
https://radiology.ucsf.edu/people/john-shepherd
Presentations
44 *UCSF authors in bold
Exosomal miR-3622a as prognostic marker in prostate cancer
Authors*: Thao Yang, Divya Bhagirath, Kirandeep Sekhon, Nathan Bucay, Shahana Majid, Varahram Shahryari, Marisa Shiina, Yutaka Hashimoto, Priyanka Kulkarni, Pritha Dasgupta, Mitsuho Imai-Sumida, Soichiro Yamamura, Z Laura Tabatabai, Kirsten Greene, Yuichiro Tanaka, Rajvir Dahiya, Guoren Deng, Sharanjot Saini
Presentation #: 4435 Presentation Date/Time: April 4, 2017, 1:00 pm - 5:00 pm Location: Section 18Presentation: Poster Session/ Board #13
Saini Research Interests: A major clinical challenge in prostate cancer is the elucidation of pathways of tumor progression, recurrence and metastasis, which could lead to the design of better diagnostic and therapeutic strategies against the disease. Towards this, our current research is primarily focused on delineating the molecular mechanisms driving prostate cancer progression, recurrence and metastasis. We are particularly interested in understanding key microRNA-mediated molecular pathways in prostate cancer with a long term objective of development of microRNAs as alternative biomarkers for the disease. We have identified important microRNA regulators of prostate cancer metastasis and also elucidated the regulatory role of key microRNAs in prostate cancer stem cells.
https://www.ncire.org/research/researchers_by_name/Sharanjot-Saini-PhD/
__________________________________________________________________________
KRAS regulates eIF4E Binding Proteins (4EBPs) via MAPK-Interacting Kinases (MNKs) in a PI3K-dependent, AKT-independent manner
Authors*: Jillian M. Silva, Rachel K. Bagni, Davide Ruggero, Frank McCormick
Presentation #: 4484 Presentation Date/Time: April 4, 2017, 1:00 pm - 5:00 pm Location: Section 21 Presentation: Poster Session/ Board #17
Presentations
45 *UCSF authors in bold
Preclinical investigation of SGN-CD70A antibody-drug conjugate in T cell lymphomas
Authors*: Chen-Yen Yang, Linlin Wang, Laura Pincus, Frank McCormick, Ryan Gill, Wei Ai
Presentation #: 4589 Presentation Date/Time: April 4, 2017, 1:00 pm - 5:00 pm Location: Section 26 Presentation: Poster Session/ Board #4
__________________________________________________________________________
Omx a hypoxia modulator reverses the immunosuppressive glioblastoma microenvironment by stimulating T cell infiltration and activation that results in increased number of long-term survivors
Authors*: Natacha Le Moan, Philberta Leung, Sarah Ng, Tina Davis, Carol Liang, Jonathan W. Winger, Stephen P. L. Cary, Nicolas Butowski, Ana Krtolica
Presentation #: 4686 Presentation Date/Time: April 4, 2017, 1:00 pm - 5:00 pm Location: Section 30 Presentation: Poster Session/ Board #2
Butowski Research Interests: My research includes translational research and a wide range of clinical trials, including those with convection-enhanced delivery (CED) with real-time MRI imaging, targeted agents, immunotherapy, and combination strategies. I am the Director of Translational Research in Neuro-Oncology and lead the translational effort on behalf of the UCSF Brain Tumor Research Center and Preclinical Core. My work has helped to create the groundwork for allied research in neuro-oncology and an extensive UCSF clinical trial portfolio for patients with primary brain and spine tumors, including an assortment of immunotherapy trials and surgically based trials. I have also designed investigator initiated trials, including a clinical trial employing intratumoral delivery with real-time MRI imaging as well as those with a range of novel targets, molecular markers and imaging biomarkers. I have also authored a number of peer-reviewed papers and presented work at national and international meetings.
https://www.ucsfhealth.org/nicholas.butowski
Presentations
46 *UCSF authors in bold
Metronomic chemotherapy prevents therapy-induced stromal activation and induction of cancer stem cells
Authors*: Kelvin K. Tsai, Tze-Sian Chan, Chung-Chi Hsu, Vincent C. Pai, Shenq-Shyang Huang, Valerie M. Weaver
Presentation #: 4763 Presentation Date/Time: April 4, 2017, 1:00 pm - 5:00 pm Location: Section 37 Presentation: Poster Session/ Board #1
Weaver Research Interests: The extracellular matrix (ECM), the noncellular component of the microenvironment, influences cell growth, survival, migration and tissue-specific differentiation through a repertoire of cellular receptors including integrins, syndecans and discoidin receptors. We are exploring the molecular mechanisms whereby these ECM receptors modulate cell fate: specifically, how mechanical and topological properties of the matrix, which are related to its composition and organization, regulate the function of matrix receptors to alter cell behavior. Our research program is broadly divided into two fields of inquiry: (1) how matrix composition and organization influences mammary tissue development and tumor progression and (2) to clarify the role of matrix force on embryonic and adult stem cell fate.
http://weaverlab.ucsf.edu
__________________________________________________________________________
A pan-cancer analysis framework for incorporating gene expression information into clinical interpretation of pediatric cancer genomic data
Authors*: Olena Morozova, Yulia Newton, Avanthi Tayi Shah, Holly Beale, Du Linh Lam, John Vivian, Isabel Bjork, Theodore Goldstein, Josh Stuart, Sofie Salama, E. Alejandro Sweet-Cordero, David Haussler
Presentation #: 4890 Presentation Date/Time: April 4, 2017, 1:00 pm - 5:00 pm Location: Section 42 Presentation: Poster Session/ Board #24
Sweet-Cordero Research Interests: My lab works to identify novel therapeutic approaches for cancer that target the genetic mutations and altered signaling networks specific to cancer cells. We use functional genomics applied to mouse and human systems (genetically engineered models, patient derived xenografts) to understand the transcriptional networks that regulate the outcome of specific oncogenic mutations and to understand how cancers become resistant to chemotherapy. We have two primary disease interests: lung cancer and pediatric sarcomas. Our lab has identified novel regulators of chemoresistance in lung cancer. We have used functional genomics in mouse and human models to identify a novel role for Wt1 in mediating KRAS-driven oncogenesis. We have identified and characterized the role of tumor-propagating cells in NSCLC and identified a key role for Notch3 as a self-renewal pathway in mouse and human NSCLC. In our sarcoma work, we are interested in mechanisms driving osteosarcoma and Ewing sarcoma progression.
https://cancer.ucsf.edu/people/profiles/sweetcordero_alejandro.8106
Presentations
47 *UCSF authors in bold
Preclinical evaluation of DNA-PK as a therapeutic target in prostate cancer
Authors*: Emanuela Dylgjeri, Jonathan F. Goodwin, Christopher M. McNair, Ayesha A. Shafi, Vishal Kothari, Felix Feng, Dana Rathkop, Karen Knudsen
Presentation #: LB-264 Presentation Date/Time: April 4, 2017, 1:00 pm - 5:00 pm Location: Section 35 Presentation: Poster Session/ Board #3
Feng Research Interests: Dr. Felix Feng is a leader in translational research in prostate cancer. The primary aim of Dr. Feng’s research program is to individualize therapy for patients with aggressive disease, by identifying determinants of treatment resistance and developing strategies to overcome this resistance. To enhance current clinical approaches from a biological perspective, his laboratory and dedicated research team are pursuing three major goals: 1) to identify novel molecular biomarkers of aggressive prostate cancer, 2) to understand the mechanisms by which several of these biomarkers drive disease progression, and 3) to develop therapeutic approaches to target these disease drivers.
https://radonc.ucsf.edu/felix-feng
__________________________________________________________________________
Technologies for Defining the Cancer Interactome
Authors*: Nevan J. Krogan
Presentation #:Presentation Date/Time: April 4, 2017, 2:45 - 4:45 PMLocation: Marquis Ballroom Salons 3-4, Meeting Level 2, Marriott Marquis DCPresentation: NIH Sponsored Session
Krogan Research Interests: Research in the Krogan lab focuses on high-throughput network biology to derive mechanistic insights into cellular processes and disease conditions, with a particular emphasis on cancer, pathogenesis, psychiatric disorders and heart disease. Cancer research and treatment is increasingly dependent on knowledge of biological networks of multiple types, including physical interactions among proteins and synthetic-lethal and epistatic interactions among genes. Dr. Krogan is Co-Director of the Cancer Cell Map Initiative (CCMI), which aims to comprehensively detail these complex interactions among cancer genes and proteins using a combination of physical interaction, genetic interaction, and computational approaches. This work will enable the analysis of cancer molecular networks with a view towards pathway and network-based personalized therapy.
http://kroganlab.ucsf.edu
Presentations
48 *UCSF authors in bold
Computational detection of oncogene‐centric pathway members
Authors*: Joshua Broyde, David Simpson, Diana Murray, Alexander Lachmann, Federico M. Giorgi, Barry Honig, Alejandro E. Sweet-Cordero, Andrea Califano
Presentation #:Presentation Date/Time: April 4, 2017, 4:05 – 4:20Location: Room 147, Level 1, Washington Convention Center Presentation: Minisymposium
Sweet-Cordero Research Interests: My lab works to identify novel therapeutic approaches for cancer that target the genetic mutations and altered signaling networks specific to cancer cells. We use functional genomics applied to mouse and human systems (genetically engineered models, patient derived xenografts) to understand the transcriptional networks that regulate the outcome of specific oncogenic mutations and to understand how cancers become resistant to chemotherapy. We have two primary disease interests: lung cancer and pediatric sarcomas. Our lab has identified novel regulators of chemoresistance in lung cancer. We have used functional genomics in mouse and human models to identify a novel role for Wt1 in mediating KRAS-driven oncogenesis. We have identified and characterized the role of tumor-propagating cells in NSCLC and identified a key role for Notch3 as a self-renewal pathway in mouse and human NSCLC. In our sarcoma work, we are interested in mechanisms driving osteosarcoma and Ewing sarcoma progression.
https://cancer.ucsf.edu/people/profiles/sweetcordero_alejandro.8106
__________________________________________________________________________
Precision Medicine: Will It Be of Benefit in Pediatric Cancer Patients
Authors*: Sabine Mueller, Charles G. Mullighan - Invited Speakers
Presentation #:Presentation Date/Time: April 4, 2017, 5:00 - 6:30 PM Location: Room 150, Level 1, Washington Convention Center Presentation: Forum
Mueller Research Interests: The laboratory of Dr. Sabine Mueller focuses on translational research in pediatric neuro-oncology. A key focus is the development and characterization of patient derived xenograft (PDX) models for diffuse intrinsic pontine gliomas (DIPG) and other pediatric high grade gliomas (pHGGs). In particular, the Mueller lab investigates the genomic heterogeneity of DIPGs and other pHGGs. Additionally, they are exploring the utility of liquid biopsies by assessing circulating tumor DNA and correlating this with disease response. Further, the laboratory is exploring central nervous system (CNS) directed delivery strategies, such as convection enhanced delivery (CED) in combination with nanotechnology, in these PDX models. The laboratory has several industry partnerships to test new agents as single agents and in combination therapy strategies with other agents as well as radiation therapy.
http://cancer.ucsf.edu/people/profiles/mueller_sabine.4800
Presentations
49 *UCSF authors in bold
Early Detection of Lethal Cancers: Separating the Wheat from the Chaff
Authors*: Avrum E. Spira, Laura J. Esserman - Invited Speakers
Presentation #:Presentation Date/Time: April 4, 2017, 5:00 - 6:30 PM Location: East Salon A-B, Level 1, Washington Convention Center Presentation: Forum
__________________________________________________________________________
Genomics and the Environment: Moving toward Precision Medicine in the Context of Health Disparities
Authors*: Laura Fejerman
Presentation #:Presentation Date/Time: April 4, 2017, 5:00 - 6:30 PMLocation: Room 152, Level 1, Washington Convention CenterPresentation Type: Forum
Fejerman Research Interests: Dr. Fejerman focuses on the discovery of genetic and non-genetic factors that contribute to breast cancer risk and prognosis in Latinas. Her past work established a relationship between genetic ancestry and breast cancer risk, where higher European ancestry in U.S. and Mexican Latinas was associated with an increased risk. Her subsequent research has built upon this observation, exploring genetic variants, through admixture mapping and genome-wide association approaches, as well as the possible environmental and lifestyle related factors, and ancestry-gene interactions. Recent work explores disparities in breast cancer prognosis by genetic ancestry in Latinas and its potential causes.
http://fejerman.ucsf.edu
Presentations
50 *UCSF authors in bold
Spatial-mechanical regulation of tumor dormancy and metastases
Authors*: Valerie M Weaver
Presentation #: Presentation Date/Time: April 4, 2017, 6:50 - 7:10 PM Location: Marquis Ballroom Salons 6-10, Meeting Level 2, Marriott Marquis DC Presentation: Town Meeting
Weaver Research Interests: The extracellular matrix (ECM), the noncellular component of the microenvironment, influences cell growth, survival, migration and tissue-specific differentiation through a repertoire of cellular receptors including integrins, syndecans and discoidin receptors. We are exploring the molecular mechanisms whereby these ECM receptors modulate cell fate: specifically, how mechanical and topological properties of the matrix, which are related to its composition and organization, regulate the function of matrix receptors to alter cell behavior. Our research program is broadly divided into two fields of inquiry: (1) how matrix composition and organization influences mammary tissue development and tumor progression and (2) to clarify the role of matrix force on embryonic and adult stem cell fate.
http://weaverlab.ucsf.edu
Presentations
51 *UCSF authors in bold
Breast cancer characteristics among Indigenous American women from Peru
Authors*: Lizeth I. Tamayo, Tatiana Vidaurr2, Jeannie N. Vásquez, Sandro Casavilca, Jessica I. A. Palomino, Monica Calderon, Garth H. Rauscher, Laura Fejerman
Presentation #: 5275 Presentation Date/Time: April 5, 2017, 8:00 am - 12:00 noon Location: Section 12 Presentation: Poster Session/ Board #3
Fejerman Research Interests: Dr. Fejerman focuses on the discovery of genetic and non-genetic factors that contribute to breast cancer risk and prognosis in Latinas. Her past work established a relationship between genetic ancestry and breast cancer risk, where higher European ancestry in U.S. and Mexican Latinas was associated with an increased risk. Her subsequent research has built upon this observation, exploring genetic variants, through admixture mapping and genome-wide association approaches, as well as the possible environmental and lifestyle related factors, and ancestry-gene interactions. Recent work explores disparities in breast cancer prognosis by genetic ancestry in Latinas and its potential causes.
http://fejerman.ucsf.edu
__________________________________________________________________________
Association of physical activity with risk of prostate cancer defined by TMPRSS2:ERG
Authors*: Claire H. Pernar, Ericka M. Ebot, Andreas Pettersson, Rebecca E. Graff, Thomas U. Ahearn, Amparo G. Gonzalez-Feliciano, Sarah C. Markt, Kathryn M. Wilson, Stephen Finn, Michelangelo Fiorentino, Edward L. Giovannucci, Lorelei A. Mucci
Presentation #: 5317 Presentation Date/Time: April 5, 2017, 8:00 am - 12:00 noon Location: Section 13 Presentation: Poster Session/ Board #15
Witte Research Interests: Our research program encompasses a synthesis of methodological and applied genetic epidemiology, with the overall aim of deciphering the mechanisms underlying complex diseases and traits (Witte, Visscher & Wray, Nature Reviews Genetics 2014). Our methods work is focused on the design and statistical analysis of next-generation sequencing and genetic association studies. We are applying these methods to studies of cancer (e.g., of the prostate), birth defects, and pharmacogenomics.
http://wittelab.ucsf.edu/pages/research
Wednesday, April 5, 2017
Presentations
52 *UCSF authors in bold
An exosomal biomarker for prostate cancer
Authors*: Divya Bhagirath, Thao Yang, Kirandeep Sekhon, Nathan Bucay, Shahana Majid, Yutaka Hashimoto, Priyanka Kulkarni, Pritha Dasgupta, Marisa Shiina, Varahram Shahryari, Mitsuho Imai-Sumida, Soichiro Yamamura, Z Laura Tabatabai, Yuichiro Tanaka, Rajvir Dahiya, Guoren Deng, Sharanjot Saini.
Presentation #: 5448 Presentation Date/Time: April 5, 2017, 8:00 am - 12:00 noon Location: Section 19 Presentation: Poster Session/ Board #13
Saini Research Interests: A major clinical challenge in prostate cancer is the elucidation of pathways of tumor progression, recurrence and metastasis, which could lead to the design of better diagnostic and therapeutic strategies against the disease. Towards this, our current research is primarily focused on delineating the molecular mechanisms driving prostate cancer progression, recurrence and metastasis. We are particularly interested in understanding key microRNA-mediated molecular pathways in prostate cancer with a long term objective of development of microRNAs as alternative biomarkers for the disease. We have identified important microRNA regulators of prostate cancer metastasis and also elucidated the regulatory role of key microRNAs in prostate cancer stem cells.
https://www.ncire.org/research/researchers_by_name/Sharanjot-Saini-PhD/
__________________________________________________________________________
VCAN promotes clear cell renal cell carcinoma tumor progression and metastasis, and predicts poor prognosis
Authors*: Yozo Mitsui, Taku Kato, Shigekatsu Maekawa, Yutaka Hashimoto, Marisa Shiina, Mitsuho Imai Sumida, Ryan Kenji Wong, Soichiro Yamamura, Varahram Shahryari, Shahana Majid, Sharanjot Saini, Guoren Deng, Rajvir Dahiya, Koichi Nakajima, Yuichiro Tanaka
Presentation #: 5749 Presentation Date/Time: April 5, 2017, 8:00 am - 12:00 noon Location: Section 37 Presentation: Poster Session/ Board #13
Tanaka Research Interests: Dr. Tanaka’s research at the UC/VA Urology Research Center San Francisco over the years has involved a variety of areas that include methylation, polymorphism, non-coding RNA, aging, gene function and signaling pathways. Specifically, his research focuses on finding risk factors for urological cancers by utilizing human specimens, assessing the functional role of these biomarkers at the cellular and molecular levels and use of animal models, and determining its regulation in the cell; as he attempts to understand the mechanisms of the carcinogenesis process. The cancer types that he’s been studying involve prostate, kidney and bladder. By engaging in his research interest, results can lead to biomarkers as well as potential therapeutic implications for urological cancers.
https://www.ncire.org/research/researchers_by_name/Yuichiro-Tanaka-PhD/
Presentations
53 *UCSF authors in bold
Disrupting the Aurora kinase A interactome in pediatric cancer
Authors*: Sucheta Mukherjee, Carolyn Tu, Clay Gustafson
Presentation #: 5818 Presentation Date/Time: April 5, 2017, 8:00 am - 12:00 noon Location: Section 40 Presentation: Poster Session/ Board #4
Gustafon Research Interests: The Gustafson lab focuses on new basic biological discoveries in cancer and leveraging these to develop novel therapies. One focus has been the discovery and development of novel targeted therapies to treat MYC driven cancers, particularly neuroblastoma. Pathways which regulate MYC proteins are central to neuroblastoma, as well as a wide array of other pediatric and adult cancers. MYCN is prominently amplified in high-risk neuroblastoma and neuroblastoma is widely considered a model MYC-protein driven disease. Most recently we have discovered a new class of conformation-disrupting Aurora A inhibitors (CD-AURKi) with CD532 as our lead compound. These CD-AURKi potently inhibit Aurora Kinase A and downregulates MYCN protein in neuroblastoma cells. Using co-crystal structures, cell culture models, and structure-activity relationships, we have shown that CD532 acts via a novel allosteric mechanism whereby a kinase inhibitor is used to drug an undruggable transcription factor.
http://gustafsonlab.ucsf.edu
__________________________________________________________________________
Androgen receptor (AR): A novel target for radiosensitization in triple-negative breast cancers (TNBC)
Authors*: Benjamin C. Chandler, Corey W. Speers, Shuang G. Zhao, Meilan Liu, Kari Wilder-Romans, Eric Olsen, Shyam Nyati, Daniel Spratt, Daniel Wahl, Daniel Hayes, Felix Y. Feng, Lori J. Pierce
Presentation #: 5839 Presentation Date/Time: April 5, 2017, 8:00 am - 12:00 noon Location: Section 41 Presentation: Poster Session/ Board #2
Feng Research Interests: Dr. Felix Feng is a leader in translational research in prostate cancer. The primary aim of Dr. Feng’s research program is to individualize therapy for patients with aggressive disease, by identifying determinants of treatment resistance and developing strategies to overcome this resistance. To enhance current clinical approaches from a biological perspective, his laboratory and dedicated research team are pursuing three major goals: 1) to identify novel molecular biomarkers of aggressive prostate cancer, 2) to understand the mechanisms by which several of these biomarkers drive disease progression, and 3) to develop therapeutic approaches to target these disease drivers.
https://radonc.ucsf.edu/felix-feng
Presentations
54 *UCSF authors in bold
Cdk4/6 kinase inhibitor resistance in prostate cancer
Authors*: Renee de Leeuw, Matthew J. Schiewer, Christopher McNair, Michael A. Augello, Akihiro Yoshida, Edward S. Hazard, Sean Courtney, Gerard T. Hardiman, Justin Drake, Felix Y. Feng, Scott Tomlins, Maha H. Hussain, J. Alan Diehl, William K. Kelly, Karen E. Knudsen
Presentation #: 5874 Presentation Date/Time: April 5, 2017, 8:00 am - 12:00 noon Location: Section 42 Presentation: Poster Session/ Board #9
Feng Research Interests: Dr. Felix Feng is a leader in translational research in prostate cancer. The primary aim of Dr. Feng’s research program is to individualize therapy for patients with aggressive disease, by identifying determinants of treatment resistance and developing strategies to overcome this resistance. To enhance current clinical approaches from a biological perspective, his laboratory and dedicated research team are pursuing three major goals: 1) to identify novel molecular biomarkers of aggressive prostate cancer, 2) to understand the mechanisms by which several of these biomarkers drive disease progression, and 3) to develop therapeutic approaches to target these disease drivers.
https://radonc.ucsf.edu/felix-feng
__________________________________________________________________________
Tumor microenvironment modulates RTK signaling
Authors*: Dhruv Thakar, Shalini T. Low-Nam, Jay T. Groves, Valerie M. Weaver
Presentation #: 5912 Presentation Date/Time: April 5, 2017, 8:00 am - 12:00 noon Location: Section 43 Presentation: Poster Session/ Board #24
Weaver Research Interests: The extracellular matrix (ECM), the noncellular component of the microenvironment, influences cell growth, survival, migration and tissue-specific differentiation through a repertoire of cellular receptors including integrins, syndecans and discoidin receptors. We are exploring the molecular mechanisms whereby these ECM receptors modulate cell fate: specifically, how mechanical and topological properties of the matrix, which are related to its composition and organization, regulate the function of matrix receptors to alter cell behavior. Our research program is broadly divided into two fields of inquiry: (1) how matrix composition and organization influences mammary tissue development and tumor progression and (2) to clarify the role of matrix force on embryonic and adult stem cell fate.
http://weaverlab.ucsf.edu
Presentations
55 *UCSF authors in bold
A novel oncomiR negatively regulates PTEN pathway in prostate cancer
Authors*: Nadeem S. Bhat, Melissa Colden, Prerna Arora, Altaf A. Dar, Sharanjot Saini, Varahram Shahryari, Soichiro Yamamura, Yuichiro Tanaka, Taku Katu, Yutaka Hashimoto, Marisa Shiina, Priyanka Kulkarni, Pritha Dasgupta, Mitsuho Imai-sumida, Shigekatsu Maekawa, Guoren Deng, Rajvir Dahiya, Shahana Majid
Presentation #: LB-326 Presentation Date/Time: April 5, 2017, 8:00 am - 12:00 noon Location: Section 36 Presentation: Poster Session/ Board #12
Majid Research Interests: The Majid lab, located Urology Research Center at the VAMC/UCSF, focuses in the area of urological cancers to understand the etiology and to develop novel molecular biomarkers for initiation, progression and metastasis with special emphasis on prostate cancer. We have been working in the field of microRNAs, genetics and epigenetics of urologic cancers. Cancer progression markers are identified by employing genome-wide approaches, and utilizing cells culture and mouse models as well as tissues from patients. The objective of the lab is to identify novel therapeutic targets or valuable biomarkers to establish rational therapeutic strategies for the diagnosis and treatment of cancer.
http://profiles.ucsf.edu/shahana.majid
__________________________________________________________________________
Glioblastoma: Where we are, where we have been, and what is next
Authors*: Michael Prados
Presentation #:Presentation Date/Time: April 5, 2017, 10:15 - 10:30 AM Location: Room 145, Level 1, Washington Convention CenterPresentation: Recent Advances in Organ Site Research
Prados Research Interests: Dr. Prados is a world-recognized Neuro-oncology expert. He led the Adult Brain Tumor Consortium for over 15 years and founded the Pacific Pediatric Neuro-Oncology Consortium (PNOC), a multi-institutional consortium of now 15 major academic centers across the United States. Currently Dr. Prados is Professor Emeritus at UCSF devoting his efforts towards pediatric Neuro-Oncology clinical and translational research. He is the co-Project Leader of a pediatric brain tumor SPORE project at UCSF and is co-Project Leader of the PNOC. His major interests are early phase clinical trials research and the translational studies that precede and inform those trials in both adults and children. He is part of the Editorial board of Neuro-Oncology, Journal of Neuro-Oncology and Journal of Clinical Oncology, and a member of the NCI/CTEP Brain Malignancies Steering Committee. In 2014 he was awarded the Victor Levin Award for lifetime clinical research excellence from the Society of Neuro-Oncology.
http://cancer.ucsf.edu/people/profiles/prados_michael.3603
56
Rahul Aggarwal, MDCT091 Safety and pharmacodynamic activity of MEDI9197, a TLR 7/8 agonist, administered intratumorally in subjects with solid tumors
Wei Ai, MD4589 Preclinical investigation of SGN-CD70A antibody-drug conjugate in T cell lymphomas
Mary Helen Barcellos-Hoff, PhD831 TGFβ controls the DNA damage response via miR-182 regulation of BRCA1 and ATM
Neil Bhola, PhD95 Targeting BRD4 overcomes cetuximab resistance in HNSCC
Trever Bivona, MD, PhD— Mechanisms of residual disease during targeted therapy
LB-124 COP1 E3 ligase modulates response to oncogenic MAPK pathway
Collin Blakely, MDCT060 STARTRK-2: A global phase 2, open-label, basket study of entrectinib in patients with locally advanced or metastatic solid tumors harboring TRK, ROS1, or ALK gene fusions
Jeffrey Bluestone, PhD683A Mechanism of liver metastasis induced systemic suppression of checkpoint inhibitor response
Nicolas Butowski, MD4686 Omx a hypoxia modulator reverses the immunosuppressive glioblastoma microenvironment by stimulating T cell infiltration and activation that results in increased number of long-term survivors
Atul Butte, MD, PhD— Characterizing tumor-adjacent normal tissue: Is it really normal?
LB-006 Oncology model fidelity scores
Rajvir Dahiya, PhD462 The role of miR-24 as a race-related genetic factor in prostate cancer
483 Differential expression of miR-34b and androgen receptor pathway regulate prostate cancer aggressiveness between African Americans and Caucasians
Summary of Abstracts
Summary of Abstracts by Faculty Member
57
Summary of Abstracts
Adil Daud, MD— Response to checkpoint therapy and exhausted CTL in the tumor microenvironment
Michel DuPage, PhD1014 Selective impairment of intratumoral regulatory T cells by targeting Ezh2 enhances cancer immunity
Laura Esserman, MD, MBA— Early Detection of Lethal Cancers: Separating the Wheat from the Chaff
Laura Fejerman, PhD— Genomics and the Environment: Moving toward Precision Medicine in the Context of Health Disparities
— Minorities in Cancer Research Scientific Symposium: The Role of Diverse Populations in Precision Medicine
5275 Breast cancer characteristics among Indigenous American women from Peru
Felix Feng, MD2546 The long noncoding RNA SChLAP1 inhibits the SWI/SNF complex, revealing a therapeutic opportunity in prostate cancer
5839 Androgen receptor (AR): A novel target for radiosensitization in triple-negative breast cancers (TNBC)
5874 Cdk4/6 kinase inhibitor resistance in prostate cancer
LB-086 PARP-1 controls the DNA damage response by regulating E2F1 transcriptional activity
LB-264 Preclinical evaluation of DNA-PK as a therapeutic target in prostate cancer
Lawrence Fong, MD549 Clustering analysis of next-generation sequencing T cell repertoire data in sipuleucel-T treated prostate cancer patients
1694 Systemic granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment increases T cell receptor diversity in localized and metastatic prostate cancer patients
CT031 A phase Ib trial to study the safety and tolerability of atezolizumab with radium-223 dichloride in patients with metastatic castrate-resistant prostate cancer (mCRPC)
CT119 CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors
Jason Gestwicki, PhD1180 Targeting the HSP40/HSP70 chaperone axis as a novel strategy to treat castration-resistant prostate cancer
Jennifer Grandis, MD— Precision medicine lessons from window-of-opportunity trials
1779 Chronic NSAID use increases survival in PIK3CA-altered head and neck squamous cell carcinoma
4101 Targeting the EGFR/STAT3 axis in NSCLC with resistance to EGFR tyrosine kinase inhibitors using an oligonucleotide-based decoy
4108 Targeting IL-6 signaling overcomes cetuximab resistance in head and neck squamous cell carcinoma
58
Summary of Abstracts
Clay Gustafson, MD, PhD5818 Disrupting the Aurora kinase A interactome in pediatric cancer
Patrick Ha, MD3577 Splice expression variation analysis (SEVA) for differential gene isoform usage in cancer
Tonya Kaltenbach, MD281 Site specific risk factors for colorectal cancer
Martin Kampmann, PhD— “Weak links” in cancer proteostasis networks as new therapeutic targets
Nevan Krogan, PhD— Technologies for Defining the Cancer Interactome
Mignon Loh, MD2642 Preclinical efficacy of daratumumab in acute lymphoblastic leukemia
Shahana Majid, PhDLB-326 A novel oncomiR negatively regulates PTEN pathway in prostate cancer
Frank McCormick, PhD435 Regulation of macropinocytosis-dependent cell survival in pancreatic cancer cells
— The NCI RAS Initiative at the Frederick National Laboratory for Cancer Research
1209 FGFR inhibition re-sensitizes BRAF/MEK dual resistant cells to the BRAF/MEK inhibitor combination
1366 Structural basis of impaired GTP hydrolysis in oncogenic mutants of KRAS
1370 EGFR-mediated Spred1 phosphorylation inhibits NF1 to sustain constitutive Ras/MAPK signaling
3182 Cytoskeletal modulation results in increased tumor survival and drug resistance through attenuation of p53 dependent apoptosis
4018 Identifying allosteric modulators of KRas using second harmonic generation
4484 KRAS regulates eIF4E Binding Proteins (4EBPs) via MAPK-Interacting Kinases (MNKs) in a PI3K-dependent, AKT-independent manner
Michael McManus, PhD1006 Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition
Sabine Mueller, MD— Precision Medicine: Will It Be of Benefit in Pediatric Cancer Patients
59
Summary of Abstracts
Pamela Munster, MDCT087 Ribociclib + endocrine therapy (ET) doublet combinations in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Phase I clinical activity and impact of molecular alterations
Jean Nakamura, MD1356 Variable drug responses characterize the functional heterogeneity of Nf1 null tumors
— Post-radiation mutational signatures
Hideho Okada, MD, PhD— Brain cancer immunotherapy
3767 Identification of a novel and a shared H3.3K27M mutation derived neoantigen epitope and H3.3K27M specific TCR engineered T cell therapy for glioma
— Vaccination in patients with low-grade glioma aiming at prevention of high-grade transformation
Susana Ortiz-Urda, MD3493 LncRNA as potential target in drug-resistant melanomas
Melike Pekmezci, MD3863 A subset of poorly prognostic pediatric posterior fossa ependymomas exhibit lowered H3K27me3 and DNA hypomethylation and show epigenetic similarities with H3K27M mutant diffuse intrinsic pontine gliomas
Claudia Petritsch, PhD916 Asymmetric cell division regulator prevents hyperproliferation in glioma cell-of-origin
Michael Prados, MDLB-008 The Pediatric Brain Tumor Atlas: building an integrated, multi-platform data-rich ecosystem for collaborative discovery in the cloud
— Glioblastoma: Where we are, where we have been, and what is next
Davide Ruggero, PhD— Translating the cancer genome one codon at a time and its therapeutic implications
Hope Rugo, MD— Transforming breast cancer treatment with CDK4/6 inhibitors
CT044 MONARCH 1: Final overall survival analysis of a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease
Amit Sabnis, MDCT030 STARTRK-NG: A phase 1/1b study of entrectinib in children and adolescents with advanced solid tumors and primary CNS tumors, with or without TRK, ROS1, or ALK fusions
60
Summary of Abstracts
Sharanjot Saini, PhD4435 Exosomal miR-3622a as prognostic marker in prostate cancer
5448 An exosomal biomarker for prostate cancer
John Shepherd, PhD4235 Application of convolutional neural networks to breast biopsies to uncover tissue correlates of mammographic breast density
Kevan Shokat, PhD— Overcoming kinase inhibitor resistance and dealing with biologic redundancy: mTOR and K-Ras
Erin Simonds, PhD3693 Single cell RNA-Seq of primary lymphomas reveals the diverse transcriptional states of the cancer immunologic milieu
Alejandro Sweet-Cordero, MD1948 Tumor-specific copy number alterations uncover therapeutic opportunities in osteosarcoma
4890 A pan-cancer analysis framework for incorporating gene expression information into clinical interpretation of pediatric cancer genomic data
— Computational detection of oncogene‐centric pathway members
Eric Talevich, PhDLB-044 Copy number estimation from targeted amplicon-based next-generation sequencing of castration-resistant prostate cancer biopsies: analytic validation and clinical qualification for a iPARP clinical trial
Yuichiro Tanaka, PhD2288 Effects of tobacco smoking and alcohol consumption on risks of CYP1B1 polymorphisms for prostate cancer
5749 VCAN promotes clear cell renal cell carcinoma tumor progression and metastasis, and predicts poor prognosis
Margaret Tempero, MD— A beginner’s guide to perplexing clinical issues in pancreatic adenocarcinoma
Laura van’t Veer, PhDLB-102 Landscape analysis of the initial data release from AACR Project GENIE
Kyle Walsh, PhD1320 Non-additive and interaction effects of HLA class 2 polymorphism contributing to risk of glioma
61
Summary of Abstracts
Valerie Weaver, PhD— Tissue Tension: The extracellular martrix and PDAC phenotype
— Forcing tumor progression and aggression
3985 NCoR2 regulates glioblastoma progression and treatment resistance
4763 Metronomic chemotherapy prevents therapy-induced stromal activation and induction of cancer stem cells
— Spatial-mechanical regulation of tumor dormancy and metastases
5912 Tumor microenvironment modulates RTK signaling
Jonathan Weissman, PhD— Retooling CRISPR to turn genes on and off
Joseph Wiemels, PhD1273 Pathway analysis of insulin-like growth factor candidate genes and risk of pediatric rhabdomyosarcoma
2263 Neonatal hormone levels and risk of testicular germ cell tumors (TGCT)
John Witte, PhD1297 Genetic reclassification of prostate-specific antigen levels for personalized prostate cancer screening
1310 Identification of pleiotropic cancer susceptibility variants from genome-wide association studies reveals functional characteristics
1316 Germline genetic signals across multiple aggressive prostate cancer phenotypes
5317 Association of physical activity with risk of prostate cancer defined by TMPRSS2:ERG
Soichiro Yamamura, PhD199 Silibinin suppresses bladder cancer through down-regulation of actin cytoskeleton and PI3K/Akt signaling pathways
3449 Genistein inhibits renal cancer progression through long non-coding RNA HOTAIR suppression
Elad Ziv, MD— Polygenic risk score for breast cancer risk prediction in Latinas: does one size fit all?
Lani Wu, PhD/Steven Altschuler, PhD3950 A novel combination therapy targeting BCL6 and phospho-STAT3 defeats intratumor heterogeneity in a subset of non-small cell lung cancers